

Index to Volume 55 (2002)

The index to Volume 55 contains a subject index and an author index.

In the **subject index**, items are listed under key words as found in the U.S. National Library of Medicine's Medical Subject Headings thesaurus.

In the **author index**, all contributing authors are listed alphabetically with the surname first and initial following. If an item has more than one author, the title is documented under the author name that appeared first when published in the *CJHP*. All other authors are listed referring to the name of the principal author, with the abbreviation "Jt Auth" indicating joint authorship.

Codes in parentheses before the page numbers indicate the nature of the item. The following codes are used in this volume:

A – Article

Abs – Abstract

CEP – Continuing Education Program

CR – Case Report

E – Editorial

EDR – Executive Director's Report

FC – On the Front Cover

IP – CSHP Information Paper

L – Letter to the Editor

POR – Presidential Officer's Report

PP – Pharmacy Practice

S – CSHP Statement

SN – Society News



Subject Index

Abciximab See **Glycoproteins**

Abstracts

- Amphotericin B: A meta-analysis of lipid versus conventional formulations (MacAulay and Martin) PPC 60
- Antipsychotic medicines: Deconstructing manufactured beliefs (Gardner) PPC 26
- Applying the WHO ATC/DDD system of drug classification in drug utilization: The promise and the pitfalls (Cooke) AGM 24
- Appropriate use of vancomycin at the Queen Elizabeth II Health Sciences (QEII HSC) and opportunity for switch from IV to oral therapy (LeBlanc and others) PPC 53
- Assessing and managing acid–base disorders in your patients (Fernandes and Wong) PPC 41
- An assessment of academic detailing (Nguyen and others) AGM 29
- Assessment of a seamless care prescription/discharge note form (Rogers and others) PPC 57
- Assessment of empiric vancomycin regimen in neonates (Newby) PPC 49
- Be still my quivering heart: Culprits and mechanisms of drug-induced arrhythmias (Tisdale) PPC 33
- The bottom line on non-ST elevation acute coronary syndromes (Paradiso-Hardy) PPC 35
- Breast cancer update (Cole) AGM 19
- Case report: Infliximab (Remicade®) induced herpes zoster (Bhajan-Mathur) PPC 60
- Characterizing patient discharge counselling activities performed by hospital pharmacists (Curran and others) AGM 34
- Clinical deterioration secondary to epoprostenol infusion interruption (Knippel and others) PPC 56
- Clinical pharmacist as information manager: Accessing the evidence where and when you need it (Loewen) AGM 27
- Clinical pharmacy technician—Reasoning and role AGM 32
- Clonidine use in intensive care unit patients: A retrospective analysis (Fairbairn and others) PPC 56
- Comparison of low dose (1 µg) cosyntropin and conventional dose (250 µg) cosyntropin for adrenal insufficiency testing in the critically ill (Yamashita and Drynan) 170
- Computer-formatted discharge medication chart (Jackson and Awdishu) PPC 58
- Computerized warfarin dosing (Foss and Dolovich) PPC 61
- Coordinated antidote distribution—A poison control centre model (Daws and others) AGM 29
- CSHP Fellows—Consistent contributors to our profession (Bayliff and others) PPC 63
- Developing a collaborative working group to advance the role of pharmacists in the care of patients with cardiovascular disease (Canadian Cardiovascular Pharmacists Network) PPC 51
- Developing a collaborative working group to advance the role of pharmacists in the care of patients with cardiovascular disease (Gordon) AGM 30
- Development and implementation process for a pharmacists educational strategy in the Regina Health District (Schuster and others) PPC 51
- Development and delivery of certificate programs for pharmacists (Winkelbauer) AGM 28
- Development of a gentamicin protocol for a community hospital (Edwards) AGM 33
- Development of a tool to assess the geriatric patient's ability for self-medication (Flanagan and MacLeod) 171
- Diltiazem-induced ileus (Woodworth and others) PPC 60
- Do Canada's hospital pharmacy management personnel have the skills they need? Results from a national survey (MacKinnon) 170
- Drug use evaluation of antidepressant (AD) drugs in the Canadian Forces (Gutschi and others) PPC 50
- Educational needs assessment for international pharmacy graduates (Austin and others) PPC 55
- Effect of live lactobacilli yogurt preparation in enterally fed patients with antibiotic associated diarrhea (Yamashita) PPC 59
- Efficacy of meropenem utilizing different dosing strategies (Muisse and others) PPC 57
- Empiric antibiotic prescribing in the intensive care unit (Salama and others) PPC 54
- Enhancement of medication utilization for patients undergoing cardiac surgery (Semchuk) PPC 48
- Entry level degree in Canada—PharmD or BSc (Hill) AGM 26
- Evaluating the impact of pharmacists' independent interventions on patient care (Brown and Szeto) PPC 56
- Evaluation of prescribing competence among physician assistants in the Canadian Forces (Vaillancourt and others) PPC 55
- Evaluation of risk factors for clostridium difficile-associated diarrhea at the Queen Elizabeth II Health Sciences Centre (Horwood and others) PPC 57
- Evaluation of usage of IV pantoprazole in a community hospital (Lakhani) AGM 29
- Examining the role of pharmacist in multidisciplinary diabetes management (Leung and others) PPC 51
- Exploration et modèle d'analyse de ratios de coûts de médicaments par indicateurs de volumes d'activités en établissement de santé (Bussièrès and Lebel) 169
- Formulary reconstruction after the amalgamation of four tertiary care hospitals to form the McGill University Health Centre (MUHC) (Pradhan and others) AGM 30
- Gene therapy in oncology (Pho) PPC 44
- Getting to know botulinum toxin (Wyllie) PPC 39
- Health care reform (Fyke) PPC 34
- Highlighting 10 years' experience with a pharmacist-directed warfarin nomogram program at a community hospital (Pao and others) PPC 48
- HIV post-exposure prophylaxis (PEP): Taking the “PEP” out of the “prick” (Park-Wyllie) PPC 38
- How more care can cost less in B.C. asthma patients (McLean and others) AGM 32
- How to turn a poster or abstract into a full-length manuscript (Ensom) AGM 18



- Impact d'une intervention visant à améliorer la conformité des ordonnances de médicaments à la règle d'émission au sein d'un établissement de santé (Bussières and Lebel) 169
- The impact of a clinical pharmacist on patient and economic outcomes on the child and adolescent mental health unit at the IWK Health Centre (Crown and Virani) PPC 56
- Impact of pharmaceutical care on dialysis patients' knowledge (Wlodarczyk and others) PPC 57
- The impact of treatment with antidepressant (AD) drug therapy on the utilization of proton pump inhibitors (PPI) or histamine 2 antagonists (H2 blockers) (Guillemette and others) PPC 53
- Implementing evidence-based antiemetic guidelines in the oncology setting: Results of a 4-month prospective intervention study (Dranitsaris and Leung) 170
- The importance of measuring antibiotic consumption in the fight against antibiotic resistance—Focus on ATC/DDD methodology (Hutchinson) AGM 24
- Improving the use of ACE inhibitors in patients with congestive heart failure: The review of education on ACE inhibitors in congestive heart failure treatment (REACT) study, stage I (Tsuyuki and others) PPC 50
- Issues in critical care (Chant and Yamashita) PPC 41
- Keeping our patients safe—A pharmacist's perspective on medical error & medication safety (Salsman) AGM 17
- Medication information by telephone: Requests reflect the needs of patients (Wichman and others) AGM 29
- A medication teaching video series for organ transplant recipients (Denesyk) 171
- Meta-analysis of amantadine and rimantadine for prophylaxis and treatment of influenza A virus infection (Marra and others) PPC 49
- Methadone maintenance: What you need to know (Isaac and Kalvic) PPC 44
- Microbiological validation of sterile preparation procedures in a pharmacy department (Bussières) 172
- Neonatal care: The pharmacists' perspective (Wong and others) PPC 42
- New medications—Paying the bill (Johnson) AGM 20
- Opportunities for pharmacy technicians: Pushing the envelope without spilling the contents (Ensom and others) AGM 21
- Optimizing and creating roles for technicians (Colquhoun) PPC 43
- Optimizing the treatment of depression: Strategies for augmenting and combining antidepressants (Zerjav) PPC 27
- Outcome analysis of a pharmacist-directed seamless care service (Nickerson and others) PPC 35
- Overcoming the side effects of antidepressants (Virani) PPC 29
- Patient assessment: The art & science of it (Dillon) AGM 23
- Patient preferences in an outpatient parenteral antibiotic therapy program (Jewesson and others) 171
- Pediatric immunizations: New agents and current controversies (Dekker) PPC 43
- Peer review and the publication process (Walker) PPC 37
- Pharmaceutical care pilot project: Provision of service in a community pharmacy using resources and knowledge of a drug information call centre (Halasi) PPC 54
- Pharmacist-initiated intravenous to oral sequential therapy (Taddei) AGM 25
- Pharmacist utilization of the DIE test to assess aminoglycoside vestibulotoxicity (Shalansky and others) 170
- A pharmacist-based lipid clinic: Development and implementation in the Canadian Forces (Vaillancourt and others) PPC 59
- Pharmacists and nurse practitioners: A partnership that works (Leblanc and Merkley) PPC 28
- Pharmacists improving patient outcomes in congestive heart failure: Results of the REACT Study (Tsuyuki) PPC 32
- Pharmacogenetics: The therapeutic drug monitoring of the future (Ensom) PPC 25
- Pharmacy educational initiative to decrease nebulization use in tertiary care hospital (Lummis) PPC 52
- Pharmacy-based heparin-induced thrombocytopenia surveillance program for heart valve replacement patients (Paradiso-Hardy and others) 169, PPC 49
- A pilot study of a possible drug interaction between *Ginkgo biloba* and warfarin (Leung and others) 169
- A pilot study on the effects of a multidisciplinary support group program in improving the adaptive life skills of heart failure patients (Chan and others) AGM 33
- Point prevalence of hyperlipidemia in HIV patients (Muisse and others) PPC 49
- Policies and planning issues around bioterrorism (Marra) AGM 25
- Prescriptive authority for pharmacists: Where are we? Where are we going? (Yuksel and Pearson) PPC 30
- The prevalence and avoidability of drug-induced admissions to an intensive care unit (Brown and Szeto) PPC 52
- A qualitative systematic review of the effects of various education strategies on pharmacists (Lee and Dolovich) PPC 53
- Randomized, controlled trial assessing the efficacy of the topical amethocaine gel to reduce pain in infants undergoing heel pricks (Patel and others) PPC 48
- A randomized trial of a patient support program for patients with congestive heart failure: The review of education on ACE inhibitors in congestive heart failure treatment (REACT) study, stage II (Tsuyuki and others) PPC 55
- Re-addressing the challenges of septic shock: A review of anticoagulation therapies (Burry) PPC 38
- Retrieving and appraising systematic reviews (Slavik) AGM 22
- Rheumatoid arthritis—New guidelines & therapies (Richardson) AGM 27
- Risk stratification, therapeutic management, and clinical outcomes of patients with non-ST elevation acute coronary syndromes: A Canadian university-affiliated hospital perspective (Shamiss and others) PPC 54
- The role of the pharmacist in an outpatient cardiac clinic (CARE—Cardiac Assessment, Risk reduction and Education service) (Bhajan-Mathur and others) PPC 58
- Seamless care: Evaluating the impact of a new discharge prescription form (Connelly and others) PPC 60



- Secondary prevention in ischemic heart disease: Utilization of antiplatelet agents in federal clients (Gutschi) PPC 58
- Self-directed learning—Myths and challenges (Schindel) AGM 26
- Shifting from inpatient to outpatient treatment of deep vein thrombosis in a tertiary care centre: A cost-minimization analysis (Boucher and others) PPC 55
- Short-term stability, accuracy, and homogeneity of morphine concentrations in syringes stored at 24°C (Seto and others) PPC 53
- Smoking cessation program for hospitalized vascular patients (Kwok and others) PPC 58
- Stability and compatibility of hydromorphone with either bupivacaine or ropivacaine in minibags stored at 4°C and 24°C (Walker and others) PPC 59
- Stability of dolestron in normal saline and 5% dextrose in water solutions stored at 4°C and 24°C in syringes (Walker and others) PPC 50
- Switching from abciximab to eptifibatid for percutaneous coronary interventions: A local analysis (SWAP study) (Leung and others) AGM 34
- A systematic review of erectile dysfunction medication literature in patients with diabetes (Halapy and Chang) PPC 52
- A systematic review of the literature on profiling physicians to promote appropriate, cost-effective prescribing (Cooke and others) AGM 33
- Telehealth Ontario—Pharmacists providing medication information to the public (Wichman) PPC 40
- Therapeutic dilemmas with anticonvulsant medications (Mejia) PPC 29
- Thinking beyond our borders: Global issues with medications (Cepuch) PPC 45
- Thinking outside the box—Challenging dogma (McCormack) AGM 17
- Tolerability of statin-fibrate and statin-niacin combination therapy in dyslipidemic patients at high risk for cardiovascular events (Pearson and others) PPC 52
- Total nutritional admixtures (Gulak) PPC 48
- Update in COPD therapeutics (Evans) AGM 18
- Update on the management of patients with cognitive impairment (Bowles) PPC 31
- Use of an in house database to promote seamless care and ongoing patient monitoring in an outpatient oncology clinic (Ritchie) AGM 30
- Use of an in-house database to promote seamless care and ongoing patient monitoring in an outpatient oncology clinic (Ritchie) PPC 59
- The use of inotropes and vasopressors in the provision of pharmaceutical care to the shock patient (Brown) PPC 39
- Use of oseltamivir during influenza outbreaks in provincial nursing homes, 1999–2000 (Bowles) 171
- Using a logic model in planning and evaluating programs and services (Marshman) PPC 32
- Using personal digital assistants (PDAs) in pharmacy practice: An overview for beginners and insights for the advanced user (Balén) PPC 26
- Valerianic acids content of commercially available valerian preparations (Draves and others) PPC 50
- What's the buzz? Identifying local patterns of drug abuse (Webb and Kent) AGM 32
- Winning strategies in the management of obesity (Berkoff) PPC 30
- The Workplace Safety and Insurance Board and Sunnybrook and Women's College Health Sciences Centre: A unique partnership (Weinstein and others) PPC 54
- Workshop on economic analysis (Jackevicius) AGM 22
- ACE inhibitors** See **Angiotensin-converting enzyme inhibitors**
- Achilles tendon**
- Levofloxacin-induced bilateral Achilles tendinopathy (Connelly and others) (CR) 212
- Acid-base imbalance**
- Assessing and managing acid-base disorders in your patients (Fernandes and Wong) (Abs) PPC 41
- Acyclovir**
- Valacyclovir neurotoxicity: Two case reports and a review of the literature (Bates) (A) 123
- Administration, oral**
- Pharmacist-initiated intravenous to oral sequential therapy (Taddei) (Abs) AGM 25
- Adrenal cortex hormones**
- Levofloxacin-induced bilateral Achilles tendinopathy (Connelly and others) (CR) 212
- Resolution of acute interstitial nephritis without steroids (Ledger and Rao) (L) 147
- Aged**
- Development of a tool to assess the geriatric patient's ability for self-medication (Flanagan and MacLeod) (Abs) 171
- Alzheimer's disease**
- Update on the management of patients with cognitive impairment (Bowles) (Abs) PPC 31
- Amantadine**
- Meta-analysis of amantadine and rimantadine for prophylaxis and treatment of influenza A virus infection (Marra and others) (Abs) PPC 49
- Ambulatory care**
- Patient preferences in an outpatient parenteral antibiotic therapy program (Jewesson and others) (Abs) 171
- A pharmacist-based lipid clinic: Development and implementation in the Canadian Forces (Vaillancourt and others) (Abs) PPC 59
- Shifting from inpatient to outpatient treatment of deep vein thrombosis in a tertiary care centre: A cost-minimization analysis (Boucher and others) (Abs) PPC 55
- Amethocaine** See **Tetracaine**
- Amphotericin B**
- Amphotericin B: A meta-analysis of lipid versus conventional formulations (MacAulay and Martin) (Abs) PPC 60
- Invasive fungal infection: Review and update of drug management (McTaggart and Wong) (CEP) (supplement to issue 2)
- Angina, unstable**
- Goal attainment scaling in the provision of pharmaceutical care to hospitalized patients with cardiovascular disease: A pilot study (Nieuwstraten and others) (A) 262
- How to evaluate pharmaco-economic data: The example of enoxaparin in acute coronary syndromes (Pharand) (A) 114



Angioedema See **Angioneurotic edema****Angioneurotic edema**

Migrating angioedema possibly related to angiotensin-converting enzyme inhibitor (Newby and Thongthai) (CR) 136

Angiotensin-converting enzyme inhibitors

2001 Canadian Hypertension Recommendations

(Leung and Yamashita) (L) 222

[reply] (Campbell) (L) 222

Improving the use of ACE inhibitors in patients with congestive heart failure: The review of education on ACE inhibitors in congestive heart failure treatment (REACT) study, stage I (Tsuyuki and others) (Abs) PPC 50

Migrating angioedema possibly related to angiotensin-converting enzyme inhibitor (Newby and Thongthai) (CR) 136

A randomized trial of a patient support program for patients with congestive heart failure: The review of education on ACE inhibitors in congestive heart failure treatment (REACT) study, stage II (Tsuyuki and others) (Abs) PPC 55

Annual General Meeting See **Congresses****Anti-infective agents, fluoroquinolone**

Fluoroquinolone-induced acute interstitial nephritis: Two case reports (MacAulay and others) (CR) 139

Levofloxacin-induced bilateral Achilles tendinopathy (Connelly and others) (CR) 212

Antibiotics

Antibiotic use in a family practice setting (Karakashian and others) (A) 198

Empiric antibiotic prescribing in the intensive care unit (Salama and others) (Abs) PPC 54

The importance of measuring antibiotic consumption in the fight against antibiotic resistance—Focus on ATC/DDD methodology (Hutchinson) (Abs) AGM 24

Antibiotics, aminoglycoside

Pharmacist utilization of the DIE test to assess aminoglycoside vestibulotoxicity (Shalansky and others) (Abs) 170

Antibodies, monoclonal

Case report: Infliximab (Remicade®) induced herpes zoster (Bhajan-Mathur) (Abs) PPC 60

Anticoagulants

Lepirudin dose recommendations for treatment of heparin-induced thrombocytopenia in patients undergoing intermittent hemodialysis (Wazny and Brackbill) (CR) 39

Re-addressing the challenges of septic shock: A review of anticoagulation therapies (Burry) (Abs) PPC 38

Venous thrombosis and the pharmacist / La thrombose veineuse et le pharmacien (Bartle and Geerts) (E) 302 / 304

Anticonvulsants

Therapeutic dilemmas with anticonvulsant medications (Mejia) (Abs) PPC 29

Antidepressive agents

Drug use evaluation of antidepressant (AD) drugs in the Canadian Forces (Gutschl and others) (Abs) PPC 50

The impact of treatment with antidepressant (AD) drug therapy on the utilization of proton pump inhibitors (PPI) or histamine 2 antagonists (H2 blockers) (Guillemette and others) (Abs) PPC 53

Overcoming the side effects of antidepressants (Virani) (Abs) PPC 29

Antidotes

Coordinated antidote distribution—A poison control centre model (Daws and others) (Abs) AGM 29

Antiemetics

Implementing evidence-based antiemetic guidelines in the oncology setting: Results of a 4-month prospective intervention study (Dranitsaris and Leung) (Abs) 170

Antifungal agents

Invasive fungal infection: Review and update of drug management (McTaggart and Wong) (CEP) (supplement to issue 2)

Antihypertensive agents

The 2001 Canadian hypertension recommendations:

What's new and what's not so new but is still important (Canadian Hypertension Recommendations Working Group) (PP) 46 [correction 337]

Antiplatelet agents See **Platelet aggregation inhibitors****Antipsychotic agents**

Antipsychotic medicines: Deconstructing manufactured beliefs (Gardner) (Abs) PPC 26

Combined olanzapine- and risperidone-induced diabetic ketoacidosis (Dahri and Brown) (L) 282

APES See **Association des pharmaciens des établissements de santé****Arrhythmia**

Be still my quivering heart: Culprits and mechanisms of drug-induced arrhythmias (Tisdale) (Abs) PPC 33

Arthritis, rheumatoid

Rheumatoid arthritis—New guidelines & therapies (Richardson) (Abs) AGM 27

Arthroplasty, replacement, hip

An economic comparison of enoxaparin and warfarin in the prevention of deep vein thrombosis after hip and knee replacement (Friesen and others) (A) 128

Arthroplasty, replacement, knee

An economic comparison of enoxaparin and warfarin in the prevention of deep vein thrombosis after hip and knee replacement (Friesen and others) (A) 128

Aspergillosis

Invasive fungal infection: Review and update of drug management (McTaggart and Wong) (CEP) (supplement to issue 2)

Association des pharmaciens des établissements de santé

Bracing for waves, smooth sailing ahead / Prêts à voguer, mer calme à l'horizon (Mann) (EDR) 14

Asthma

How more care can cost less in B.C. asthma patients (McLean and others) (Abs) AGM 32

Awards and prizes

Award-winning abstracts, Professional Practice Conference 2002 (SN) 169

Awards presentations at 2002 Professional Practice Conference (SN) 163



CSHP Awards Program (SN) 12

Isabel E. Stauffer Meritorious Service Award winner for 2001/2002: Marg Colquhoun (SN) 158

Ortho Distinguished Service Award winner for 2000/2001: Glen R. Brown (SN) 159

Striving for excellence ... with great success! / À la recherche de l'excellence : un véritable succès ! (Mann) (EDR) 104

Azoles

Invasive fungal infection: Review and update of drug management (McTaggart and Wong) (CEP) (supplement to issue 2)

Barrier isolators See **Equipment and supplies, hospital Base composition**

The Human Genome Project (Walker) (FC) 4

Base sequence

The Human Genome Project (Walker) (FC) 4

Biological safety cabinet See **Equipment and supplies, hospital**

Biological warfare

Policies and planning issues around bioterrorism (Marra) (Abs) AGM 25

Bioterrorism See **Biological warfare**

Botulinum toxins

Getting to know botulinum toxin (Wyllie) (Abs) PPC 39

Breast neoplasms

Breast cancer update (Cole) (Abs) AGM 19

Treating genetic disease (Walker) (FC) 96

Who owns your genes? (Walker) (FC) 248

Canada

An information paper on pharmacist prescribing within a health care facility (Pearson and others) (IP) 56

Medication safety alerts (U) (PP) 219

Professional boundaries / Les limites de la profession (Dupuis) (E) 98 / 102

Canadian Association of Pharmacy Students and Interns

Bracing for waves, smooth sailing ahead / Prêts à voguer, mer calme à l'horizon (Mann) (EDR) 14

La SCPH se démarque encore / CSHP—Still making a difference (Poloway) (POR) 181 / 184

Canadian Association of Pharmacy Technicians

La SCPH se démarque encore / CSHP—Still making a difference (Poloway) (POR) 181 / 184

Canadian Cardiovascular Pharmacists Network

Developing a collaborative working group to advance the role of pharmacists in the care of patients with cardiovascular disease (Gordon) (Abs) AGM 30

Canadian Hypertension Recommendations Working Group

The 2001 Canadian hypertension recommendations: What's new and what's not so new but is still important (Canadian Hypertension Recommendations Working Group) (PP) 46 [correction 337]

2001 Canadian Hypertension Recommendations (Leung and Yamashita) (L) 222 [reply] (Campbell) (L) 222

Canadian Journal of Hospital Pharmacy

Instructions to authors 88, 292

Canadian Society of Hospital Pharmacists

AGM 2002: A time to review, a time to renew / AGA 2002 : Un vent de réflexion, un vent de renouveau (Gray) (POR) 356 / 358

Awards presentations at 2002 Professional Practice Conference (SN) 163

Bracing for waves, smooth sailing ahead / Prêts à voguer, mer calme à l'horizon (Mann) (EDR) 14

CSHP

55th Annual General Meeting and Educational Sessions (SN) 349

Awards Program (SN) 12

Corporate Members 2002 (SN) 6

Executive and council (SN) 4

Faculty (SN) 65

Fellows (SN) 63, 161

Fellows—Consistent contributors to our profession (Bayliff and others) (Abs) PPC 63

Past Presidents (SN) 62

CSHP President Mike Gaucher: A vision of success / Président de la SCPH, Mike Gaucher a une vision de la réussite (SN) 347 / 348

In memory of Isabel Stauffer, "First Lady of Hospital Pharmacy" (SN) 354

An information paper on pharmacist prescribing within a health care facility (Pearson and others) (IP) 56

Isabel E. Stauffer Meritorious Service Award winner for 2001/2002: Marg Colquhoun (SN) 158

Mistakes killing patients! / Erreurs fatales ! (MacKeigan) (E) 6 / 10

New director for U of T's PharmD Program: Dr Tom Brown (SN) 350

Notice to members: Changes to the CSHP Bylaws / Avis aux membres : Changements aux statuts et règlements de la SCPH (SN) 232 / 233

Ortho Distinguished Service Award winner for 2000/2001: Glen R. Brown (SN) 159

Le pharmacien prescripteur : à la recherche de l'excellence des soins aux patients / Pharmacist prescribing: Striving for excellence in patient care (Gray) (POR) 90 / 92

Président élu ? Qui ? Moi ? / President Elect—who, me? (Johnson) (POR) 295 / 296

Research as an avenue to invigorate your practice? / La recherche : un souffle nouveau à la pratique ? (Ensom) (E) 250 / 252

Riding the waves ... team CSHP in action / Voguer la galère ... équipe SCPH en action (Mann) (EDR) 197

La SCPH appelée à l'action ! / CSHP—Called to action! (Gaucher) (POR) 243 / 244

La SCPH se démarque encore / CSHP—Still making a difference (Poloway) (POR) 181 / 184

Statement on pharmacist prescribing (Pearson and others) (S) 55

Striving for excellence ... with great success! / À la recherche de l'excellence : un véritable succès ! (Mann) (EDR) 104

York Central Hospital announces new Director of Pharmacy Services (SN) 350



Candidemia See **Candidiasis****Candidiasis**

Invasive fungal infection: Review and update of drug management (McTaggart and Wong) (CEP) (supplement to issue 2)

CAPSI See **Canadian Association of Pharmacy Students and Interns****Carbapenems**

Efficacy of meropenem utilizing different dosing strategies (Muisse and others) (Abs) PPC 57

Cardiac care facilities

The role of the pharmacist in an outpatient cardiac clinic (CARE—Cardiac Assessment, Risk reduction and Education service) (Bhajan-Mathur and others) (Abs) PPC 58

Cardiac surgery See **Thoracic surgery****Cardiology**

Quality improvement initiative for pharmacist-assisted warfarin dosing: Implementation and evaluation of a new protocol (To and Jackevicius) (A) 105

Cardiotonic agents

The use of inotropes and vasopressors in the provision of pharmaceutical care to the shock patient (Brown) (Abs) PPC 39

Cardiovascular diseases

Developing a collaborative working group to advance the role of pharmacists in the care of patients with cardiovascular disease (Canadian Cardiovascular Pharmacists Network) (Abs) PPC 51

Developing a collaborative working group to advance the role of pharmacists in the care of patients with cardiovascular disease (Gordon) (Abs) AGM 30

Goal attainment scaling in the provision of pharmaceutical care to hospitalized patients with cardiovascular disease: A pilot study (Nieuwstraten and others) (A) 262

Risk stratification, therapeutic management, and clinical outcomes of patients with non-ST elevation acute coronary syndromes: A Canadian university-affiliated hospital perspective (Shamiss and others) (Abs) PPC 54

Caspofungin See **Antifungal agents****Catheterization, central venous**

Invasive fungal infection: Review and update of drug management (McTaggart and Wong) (CEP) (supplement to issue 2)

Central nervous system

Valacyclovir neurotoxicity: Two case reports and a review of the literature (Bates) (A) 123

Cerebral ischemia, transient

The 2001 Canadian hypertension recommendations: What's new and what's not so new but is still important (Canadian Hypertension Recommendations Working Group) (PP) 46 [correction 337]

Cerebrovascular disorders

The 2001 Canadian hypertension recommendations: What's new and what's not so new but is still important (Canadian Hypertension Recommendations Working Group) (PP) 46 [correction 337]

Child

Total parenteral nutrition practices in Canadian neonatal and pediatric care units: Results of a survey (Wlodarczyk and others) (A) 254

Cholinesterase inhibitors

Update on the management of patients with cognitive impairment (Bowles) (Abs) PPC 31

Ciprofloxacin

Fluoroquinolone-induced acute interstitial nephritis: Two case reports (MacAulay and others) (CR) 139
Resolution of acute interstitial nephritis without steroids (Ledger and Rao) (L) 147

Clonidine

Clonidine use in intensive care unit patients: A retrospective analysis (Fairbairn and others) (Abs) PPC 56

Colorectal neoplasms, hereditary nonpolyposis

Treating genetic disease (Walker) (FC) 96

Communication

Medication safety alerts (U) (PP) 143

Quantifying the impact of prescription-related problems on pharmacy workload (Fok and Lo) (A) 313

Community pharmacy services

Medication safety alerts (U) (PP) 143

Pharmaceutical care pilot project: Provision of service in a community pharmacy using resources and knowledge of a drug information call centre (Halasi) (Abs) PPC 54

Conferences See **Congresses****Congresses**

AGM 2002: A time to review, a time to renew / AGA 2002 : Un vent de réflexion, un vent de renouveau (Gray) (POR) 356 / 358

Award-winning abstracts, Professional Practice Conference 2002 (SN) 169

Awards presentations at 2002 Professional Practice Conference (SN) 163

Bracing for waves, smooth sailing ahead / Prêts à voguer, mer calme à l'horizon (Mann) (EDR) 14

CSHP 55th Annual General Meeting and Educational Sessions (SN) 349

Riding the waves ... team CSHP in action / Voguer la galère ... équipe SCPH en action (Mann) (EDR) 197

Striving for excellence ... with great success! / À la recherche de l'excellence : un véritable succès ! (Mann) (EDR) 104

Continuity of patient care

Assessment of a seamless care prescription/discharge note form (Rogers and others) (Abs) PPC 57

Medication safety alerts (U) (PP) 143

Outcome analysis of a pharmacist-directed seamless care service (Nickerson and others) (Abs) PPC 35

Seamless care: Evaluating the impact of a new discharge prescription form (Connelly and others) (Abs) PPC 60

Corticosteroids See **Adrenal cortex hormones****Costs and cost analysis**

Audit of IV pantoprazole: Patterns of use and compliance with guidelines (Cornish and others) (A) 20

Coordinated antidote distribution—A poison control centre model (Daws and others) (Abs) AGM 29



- An economic comparison of enoxaparin and warfarin in the prevention of deep vein thrombosis after hip and knee replacement (Friesen and others) (A) 128
- How more care can cost less in B.C. asthma patients (McLean and others) (Abs) AGM 32
- How to evaluate pharmacoeconomic data: The example of enoxaparin in acute coronary syndromes (Pharand) (A) 114
- The impact of a clinical pharmacist on patient and economic outcomes on the child and adolescent mental health unit at the IWK Health Centre (Crown and Virani) (Abs) PPC 56
- Pharmacogenomics (Walker) (FC) 188
- Shifting from inpatient to outpatient treatment of deep vein thrombosis in a tertiary care centre: A cost-minimization analysis (Boucher and others) (Abs) PPC 55
- Workshop on economic analysis (Jackevicius) (Abs) AGM 22
- Cosyntropin**
- Comparison of low dose (1 µg) cosyntropin and conventional dose (250 µg) cosyntropin for adrenal insufficiency testing in the critically ill (Yamashita and Drynan) (Abs) 170
- CPA** See **Canadian Pharmacists Association**
- Critical care**
- Issues in critical care (Chant and Yamashita) (Abs) PPC 41
- Dalteparin** See **Tedelparin**
- Danaparoid** See **Anticoagulants**
- Data collection**
- La SCPH appelée à l'action ! / CSHP—Called to action! (Gaucher) (POR) 243 / 244
- Databases**
- Use of an in house database to promote seamless care and ongoing patient monitoring in an outpatient oncology clinic (Ritchie) (Abs) AGM 30
- Use of an in-house database to promote seamless care and ongoing patient monitoring in an outpatient oncology clinic (Ritchie) (Abs) PPC 59
- Deaths**
- In memory of Isabel Stauffer, "First Lady of Hospital Pharmacy" (SN) 354
- Obituary: F. Norman Hughes (SN) 177
- Depression**
- Optimizing the treatment of depression: Strategies for augmenting and combining antidepressants (Zerjav) (Abs) PPC 27
- Developing countries**
- Thinking beyond our borders: Global issues with medications (Cepuch) (Abs) PPC 45
- Dexamethasone**
- Stability and compatibility of granisetron alone and in combination with dexamethasone in 0.9% sodium chloride and 5% dextrose in water solutions (Walker and Law) (A) 27
- Diabetes mellitus**
- The 2001 Canadian hypertension recommendations: What's new and what's not so new but is still important (Canadian Hypertension Recommendations Working Group) (PP) 46 [correction 337]
- Combined olanzapine- and risperidone-induced diabetic ketoacidosis (Dahri and Brown) (L) 282
- Examining the role of pharmacist in multidisciplinary diabetes management (Leung and others) (Abs) PPC 51
- A systematic review of erectile dysfunction medication literature in patients with diabetes (Halapy and Chang) (Abs) PPC 52
- Diabetic ketoacidosis**
- Combined olanzapine- and risperidone-induced diabetic ketoacidosis (Dahri and Brown) (L) 282
- Dialysis**
- Impact of pharmaceutical care on dialysis patients' knowledge (Wlodarczyk and others) (Abs) PPC 57
- Diarrhea**
- Effect of live lactobacilli yogurt preparation in enterally fed patients with antibiotic associated diarrhea (Yamashita) (Abs) PPC 59
- Evaluation of risk factors for clostridium difficile-associated diarrhea at the Queen Elizabeth II Health Sciences Centre (Horwood and others) (Abs) PPC 57
- Dibenzothiazepines**
- Combined olanzapine- and risperidone-induced diabetic ketoacidosis (Dahri and Brown) (L) 282
- DIE test** See **Vestibular function tests**
- Diltiazem**
- Diltiazem-induced ileus (Woodworth and others) (Abs) PPC 60
- Dimenhydrinate**
- Chemical stability of dimenhydrinate in minibags and polypropylene syringes (Donnelly) (A) 307
- Documentation**
- Application of personal digital assistants to an infectious diseases consult service (Ong and Tailor) (L) 281
- Dolestron**
- Stability of dolestron in normal saline and 5% dextrose in water solutions stored at 4°C and 24°C in syringes (Walker and others) (Abs) PPC 50
- Drug administration schedule**
- A comparison of 2 dosage regimens of intravenous vancomycin in hemodialysis patients (Harder and others) (Abs) 172
- Drug combinations**
- Tolerability of statin-fibrate and statin-niacin combination therapy in dyslipidemic patients at high risk for cardiovascular events (Pearson and others) (Abs) PPC 52
- Drug costs**
- Exploration et modèle d'analyse de ratios de coûts de médicaments par indicateurs de volumes d'activités en établissement de santé (Bussièrès and Lebel) (Abs) 169
- New medications—Paying the bill (Johnson) (Abs) AGM 20
- Drug incompatibility**
- Stability and compatibility of granisetron alone and in combination with dexamethasone in 0.9% sodium chloride and 5% dextrose in water solutions (Walker and Law) (A) 27
- Drug interactions**
- A pilot study of a possible drug interaction between *Ginkgo biloba* and warfarin (Leung and others) (Abs) 169
- Therapeutic dilemmas with anticonvulsant medications (Mejia) (Abs) PPC 29



Drug labelling

Medication safety alerts (U) (PP) 219, 278

Drug monitoring

Anti-factor Xa monitoring in overweight and obese patients (Wilbur) (L) 336

Arguments against monitoring levels of anti-factor Xa in conjunction with low-molecular-weight heparin therapy (Rosenbloom and Ginsberg) (A) 15

Lepirudin dose recommendations for treatment of heparin-induced thrombocytopenia in patients undergoing intermittent hemodialysis (Wazny and Brackbill) (CR) 39

Pharmacogenetics: The therapeutic drug monitoring of the future (Ensom) (Abs) PPC 25

Drug stability

Chemical stability of dimenhydrinate in minibags and polypropylene syringes (Donnelly) (A) 307

Short-term stability, accuracy, and homogeneity of morphine concentrations in syringes stored at 24°C (Seto and others) (Abs) PPC 53

Stability and compatibility of granisetron alone and in combination with dexamethasone in 0.9% sodium chloride and 5% dextrose in water solutions (Walker and Law) (A) 27

Stability and compatibility of hydromorphone with either bupivacaine or ropivacaine in minibags stored at 4°C and 24°C (Walker and others) (Abs) PPC 59

Stability of dolestron in normal saline and 5% dextrose in water solutions stored at 4°C and 24°C in syringes (Walker and others) (Abs) PPC 50

Stability of mycophenolate mofetil in a 1:1 mixture of Ora-Sweet and Ora-Plus (Ensom and Decarie) (L) 63

Stability of oxycodone hydrochloride for injection in dextrose and saline solutions (Turnbull and others) (A) 272

Stability of trimethoprim in admixtures of trimethoprim-sulfamethoxazole prepared in polyvinylchloride bags and glass bottles (Curtis and Edwards) (A) 207

Drug storage

Chemical stability of dimenhydrinate in minibags and polypropylene syringes (Donnelly) (A) 307

Short-term stability, accuracy, and homogeneity of morphine concentrations in syringes stored at 24°C (Seto and others) (Abs) PPC 53

Stability and compatibility of granisetron alone and in combination with dexamethasone in 0.9% sodium chloride and 5% dextrose in water solutions (Walker and Law) (A) 27

Stability and compatibility of hydromorphone with either bupivacaine or ropivacaine in minibags stored at 4°C and 24°C (Walker and others) (Abs) PPC 59

Stability of dolestron in normal saline and 5% dextrose in water solutions stored at 4°C and 24°C in syringes (Walker and others) (Abs) PPC 50

Stability of mycophenolate mofetil in a 1:1 mixture of Ora-Sweet and Ora-Plus (Ensom and Decarie) (L) 63

Stability of oxycodone hydrochloride for injection in dextrose and saline solutions (Turnbull and others) (A) 272

Stability of trimethoprim in admixtures of trimethoprim-sulfamethoxazole prepared in polyvinylchloride bags and glass bottles (Curtis and Edwards) (A) 207

Drug therapy

Pharmacogenomics (Walker) (FC) 188

Drug toxicity

Invasive fungal infection: Review and update of drug management (McTaggart and Wong) (CEP) (supplement to issue 2)

Valacyclovir neurotoxicity: Two case reports and a review of the literature (Bates) (A) 123

Drug utilization

Antibiotic use in a family practice setting (Karakashian and others) (A) 198

Applying the WHO ATC/DDD system of drug classification in drug utilization: The promise and the pitfalls (Cooke) (Abs) AGM 24

Appropriate use of vancomycin at the Queen Elizabeth II Health Sciences (QEII HSC) and opportunity for switch from IV to oral therapy (LeBlanc and others) (Abs) PPC 53

Audit of IV pantoprazole: Patterns of use and compliance with guidelines (Cornish and others) (A) 20

Drug use evaluation of antidepressant (AD) drugs in the Canadian Forces (Gutschi and others) (Abs) PPC 50

Empiric antibiotic prescribing in the intensive care unit (Salama and others) (Abs) PPC 54

Evaluation of usage of IV pantoprazole in a community hospital (Lakhani) (Abs) AGM 29

The importance of measuring antibiotic consumption in the fight against antibiotic resistance—Focus on ATC/DDD methodology (Hutchinson) (Abs) AGM 24

Secondary prevention in ischemic heart disease: Utilization of antiplatelet agents in federal clients (Gutschi) (Abs) PPC 58

Dyslipidemia See Hyperlipidemia

Echinocandins See Antifungal agents

Economics, hospital

An economic comparison of enoxaparin and warfarin in the prevention of deep vein thrombosis after hip and knee replacement (Friesen and others) (A) 128

Economics, pharmaceutical

How to evaluate pharmaco-economic data: The example of enoxaparin in acute coronary syndromes (Pharand) (A) 114

Editorials

Mistakes killing patients! / Erreurs fatales! (MacKeigan) (E) 6 / 10

Professional boundaries / Les limites de la profession (Dupuis) (E) 98 / 102

Research as an avenue to invigorate your practice? / La recherche : un souffle nouveau à la pratique? (Ensom) (E) 250 / 252

Teaching and mentorship: Invaluable contributions to the profession / Enseignement et mentorat : de précieuses contributions à la profession (Tisdale) (E) 192 / 195

Venous thrombosis and the pharmacist / La thrombose veineuse et le pharmacien (Bartle and Geerts) (E) 302 / 304



Education

An assessment of academic detailing (Nguyen and others) (Abs) AGM 29

Education, pharmacy

AGM 2002: A time to review, a time to renew / AGA 2002 : Un vent de réflexion, un vent de renouveau (Gray) (POR) 356 / 358

Development and delivery of certificate programs for pharmacists (Winkelbauer) (Abs) AGM 28

Entry level degree in Canada—PharmD or BSc (Hill) (Abs) AGM 26

New director for U of T's PharmD Program: Dr Tom Brown (SN) 350

Teaching and mentorship: Invaluable contributions to the profession / Enseignement et mentorat : de précieuses contributions à la profession (Tisdale) (E) 192 / 195

Education, pharmacy, continuing

AGM 2002: A time to review, a time to renew / AGA 2002 : Un vent de réflexion, un vent de renouveau (Gray) (POR) 356 / 358

Development and implementation process for a pharmacists educational strategy in the Regina Health District (Schuster and others) (Abs) PPC 51

A qualitative systematic review of the effects of various education strategies on pharmacists (Lee and Dolovich) (Abs) PPC 53

Emergency Care Research Institute

Medication safety alerts (U) (PP) 52

Enoxaparin

An economic comparison of enoxaparin and warfarin in the prevention of deep vein thrombosis after hip and knee replacement (Friesen and others) (A) 128

How to evaluate pharmacoeconomic data: The example of enoxaparin in acute coronary syndromes (Pharand) (A) 114

Epinephrine

Medication safety alerts (U) (PP) 330

Eptifibatide See Glycoproteins

Equipment and supplies, hospital

Microbiological validation of sterile preparation procedures in a pharmacy department (Bussi eres) (Abs) 172

Erectile dysfunction See Impotence

Esophagitis

Audit of IV pantoprazole: Patterns of use and compliance with guidelines (Cornish and others) (A) 20

Evidence-based medicine

Retrieving and appraising systematic reviews (Slavik) (Abs) AGM 22

Thinking outside the box—Challenging dogma (McCormack) (Abs) AGM 17

Factor Xa

Anti-factor Xa monitoring in overweight and obese patients (Wilbur) (L) 336

Arguments against monitoring levels of anti-factor Xa in conjunction with low-molecular-weight heparin therapy (Rosenbloom and Ginsberg) (A) 15

Family practice

Antibiotic use in a family practice setting (Karakashian and others) (A) 198

Development of a pharmacist-managed preventive medication assessment program in a family physician office setting: The medication checkup (Kennie and Bajcar) (A) 320

Fluconazole

Invasive fungal infection: Review and update of drug management (McTaggart and Wong) (CEP) (supplement to issue 2)

Fluoroquinolone See Anti-infective agents, fluoroquinolone

Formularies, hospital

Formulary considerations related to warfarin interchangeability (Sawoniak and others) (PP) 215

Formulary reconstruction after the amalgamation of four tertiary care hospitals to form the McGill University Health Centre (MUHC) (Pradhan and others) (Abs) AGM 30

How to evaluate pharmacoeconomic data: The example of enoxaparin in acute coronary syndromes (Pharand) (A) 114

Front cover

Brave new world? (Walker) (FC) 300

The Human Genome Project (Walker) (FC) 4

Pharmacogenomics (Walker) (FC) 188

Treating genetic disease (Walker) (FC) 96

Who owns your genes? (Walker) (FC) 248

Furosemide

Medication safety alerts (U) (PP) 219

Gastrointestinal hemorrhage

Audit of IV pantoprazole: Patterns of use and compliance with guidelines (Cornish and others) (A) 20

Genetics, medical

Brave new world? (Walker) (FC) 300

The Human Genome Project (Walker) (FC) 4

Pharmacogenomics (Walker) (FC) 188

Treating genetic disease (Walker) (FC) 96

Who owns your genes? (Walker) (FC) 248

Gentamicins

Development of a gentamicin protocol for a community hospital (Edwards) (Abs) AGM 33

Ginkgo biloba See Medicine, herbal

Glycoproteins

Switching from abciximab to eptifibatide for percutaneous coronary interventions: A local analysis (SWAP study) (Leung and others) (Abs) AGM 34

Goal attainment scaling See Outcome assessment (health care)

Granisetron

Stability and compatibility of granisetron alone and in combination with dexamethasone in 0.9% sodium chloride and 5% dextrose in water solutions (Walker and Law) (A) 27

Health care reform

Health care reform (Fyke) (Abs) PPC 34

Health manpower

Medication safety alerts (U) (PP) 330

Riding the waves ... team CSHP in action / Voguer la gal erie ...  quipe SCPH en action (Mann) (EDR) 197



La SCPH se démarque encore / CSHP—Still making a difference (Poloway) (POR) 181 / 184

Heart diseases

The bottom line on non-ST elevation acute coronary syndromes (Paradiso-Hardy) (Abs) PPC 35

Heart failure, congestive

Improving the use of ACE inhibitors in patients with congestive heart failure: The review of education on ACE inhibitors in congestive heart failure treatment (REACT) study, stage I (Tsuyuki and others) (Abs) PPC 50

A pilot study on the effects of a multidisciplinary support group program in improving the adaptive life skills of heart failure patients (Chan and others) (Abs) AGM 33

A randomized trial of a patient support program for patients with congestive heart failure: The review of education on ACE inhibitors in congestive heart failure treatment (REACT) study, stage II (Tsuyuki and others) (Abs) PPC 55

Heart valve prosthesis

Pharmacy-based heparin-induced thrombocytopenia surveillance program for heart valve replacement patients (Paradiso-Hardy and others) (Abs) 169, PPC 49

Hemodialysis

A comparison of 2 dosage regimens of intravenous vancomycin in hemodialysis patients (Harder and others) (Abs) 172

Lepirudin dose recommendations for treatment of heparin-induced thrombocytopenia in patients undergoing intermittent hemodialysis (Wazny and Brackbill) (CR) 39

Hemorrhage

Arguments against monitoring levels of anti-factor Xa in conjunction with low-molecular-weight heparin therapy (Rosenbloom and Ginsberg) (A) 15

Heparin

An economic comparison of enoxaparin and warfarin in the prevention of deep vein thrombosis after hip and knee replacement (Friesen and others) (A) 128

Lepirudin dose recommendations for treatment of heparin-induced thrombocytopenia in patients undergoing intermittent hemodialysis (Wazny and Brackbill) (CR) 39

Pharmacy-based heparin-induced thrombocytopenia surveillance program for heart valve replacement patients (Paradiso-Hardy and others) (Abs) 49

Heparin, low-molecular-weight

Anti-factor Xa monitoring in overweight and obese patients (Wilbur) (L) 336

Arguments against monitoring levels of anti-factor Xa in conjunction with low-molecular-weight heparin therapy (Rosenbloom and Ginsberg) (A) 15

An economic comparison of enoxaparin and warfarin in the prevention of deep vein thrombosis after hip and knee replacement (Friesen and others) (A) 128

How to evaluate pharmacoeconomic data: The example of enoxaparin in acute coronary syndromes (Pharand) (A) 114

Hereditary diseases

Treating genetic disease (Walker) (FC) 96

Herpes zoster

Case report: Infliximab (Remicade®) induced herpes zoster (Bhajan-Mathur) (Abs) PPC 60

Hip replacement See **Arthroplasty, replacement, hip**

HIV
HIV post-exposure prophylaxis (PEP): Taking the “PEP” out of the “prick” (Park-Wyllie) (Abs) PPC 38

Point prevalence of hyperlipidemia in HIV patients (Muise and others) (Abs) PPC 49

Home care services

Patient preferences in an outpatient parenteral antibiotic therapy program (Jewesson and others) (Abs) 171

Hospital incident reporting See **Risk management**

Human Genome Project

Brave new world? (Walker) (FC) 300

The Human Genome Project (Walker) (FC) 4

Pharmacogenomics (Walker) (FC) 188

Treating genetic disease (Walker) (FC) 96

Who owns your genes? (Walker) (FC) 248

Hydromorphone

Stability and compatibility of hydromorphone with either bupivacaine or ropivacaine in minibags stored at 4°C and 24°C (Walker and others) (Abs) PPC 59

Hyperaldosteronism

The 2001 Canadian hypertension recommendations: What's new and what's not so new but is still important (Canadian Hypertension Recommendations Working Group) (PP) 46 [correction 337]

Hyperlipidemia

A pharmacist-based lipid clinic: Development and implementation in the Canadian Forces (Vaillancourt and others) (Abs) PPC 59

Point prevalence of hyperlipidemia in HIV patients (Muise and others) (Abs) PPC 49

Tolerability of statin–fibrate and statin–niacin combination therapy in dyslipidemic patients at high risk for cardiovascular events (Pearson and others) (Abs) PPC 52

Hypertension

The 2001 Canadian hypertension recommendations: What's new and what's not so new but is still important (Canadian Hypertension Recommendations Working Group) (PP) 46 [correction 337]

2001 Canadian Hypertension Recommendations

(Leung and Yamashita) (L) 222

[reply] (Campbell) (L) 222

Hypertension, renovascular

The 2001 Canadian hypertension recommendations: What's new and what's not so new but is still important (Canadian Hypertension Recommendations Working Group) (PP) 46 [correction 337]

Ileus See **Intestinal obstruction**

Immunization

Pediatric immunizations: New agents and current controversies (Dekker) (Abs) PPC 43

Immunosuppressive agents

A medication teaching video series for organ transplant recipients (Denesyk) (Abs) 171

Stability of mycophenolate mofetil in a 1:1 mixture of Ora-Sweet and Ora-Plus (Ensom and Decarie) (L) 63



Impotence

A systematic review of erectile dysfunction medication literature in patients with diabetes (Halapy and Chang) (Abs) PPC 52

Indomethacin

Postpartum indomethacin-associated psychosis (Lyons and Cronje) (L) 63

Infant

Pediatric immunizations: New agents and current controversies (Dekker) (Abs) PPC 43

Total parenteral nutrition practices in Canadian neonatal and pediatric care units: Results of a survey (Wlodarczyk and others) (A) 254

Infant, newborn

Assessment of empiric vancomycin regimen in neonates (Newby) (Abs) PPC 49

Neonatal care: The pharmacists' perspective (Wong and others) (Abs) PPC 42

Randomized, controlled trial assessing the efficacy of the topical amethocaine gel to reduce pain in infants undergoing heel pricks (Patel and others) (Abs) PPC 48

Total parenteral nutrition practices in Canadian neonatal and pediatric care units: Results of a survey (Wlodarczyk and others) (A) 254

Infliximab See **Antibodies, monoclonal**

Influenza

Use of oseltamivir during influenza outbreaks in provincial nursing homes, 1999–2000 (Bowles) (Abs) 171

Influenza A virus

Meta-analysis of amantadine and rimantadine for prophylaxis and treatment of influenza A virus infection (Marra and others) (Abs) PPC 49

Information services

Medication information by telephone: Requests reflect the needs of patients (Wichman and others) (Abs) AGM 29

Telehealth Ontario—Pharmacists providing medication information to the public (Wichman) (Abs) PPC 40

Information systems

Application of personal digital assistants to an infectious diseases consult service (Ong and Tailor) (L) 281

Using personal digital assistants (PDAs) in pharmacy practice: An overview for beginners and insights for the advanced user (Balén) (Abs) PPC 26

Infusion pumps

Clinical deterioration secondary to epoprostenol infusion interruption (Knippel and others) (Abs) PPC 56

Inotropic agents, positive cardiac See **Cardiotonic agents**

Institute for Safe Medication Practices

Medication safety alerts (U) (PP) 52, 143, 219, 278, 330
Mistakes killing patients! / Erreurs fatales! (MacKeigan) (E) 6 / 10

Intensive care units

Clonidine use in intensive care unit patients: A retrospective analysis (Fairbairn and others) (Abs) PPC 56

Empiric antibiotic prescribing in the intensive care unit (Salama and others) (Abs) PPC 54

The prevalence and avoidability of drug-induced admissions to an intensive care unit (Brown and Szeto) (Abs) PPC 52

International normalized ratio

Formulary considerations related to warfarin interchangeability (Sawoniak and others) (PP) 215

Quality improvement initiative for pharmacist-assisted warfarin dosing: Implementation and evaluation of a new protocol (To and Jackevicius) (A) 105

International pharmacy graduates See **Pharmacists**

Interprofessional relations

Pharmacists and nurse practitioners: A partnership that works (Leblanc and Merkley) (Abs) PPC 28

Intestinal obstruction

Diltiazem-induced ileus (Woodworth and others) (Abs) PPC 60

Isabel E. Stauffer Meritorious Service Award See **Awards and prizes**

ISMIP See **Institute for Safe Medication Practices**

Itraconazole

Invasive fungal infection: Review and update of drug management (McTaggart and Wong) (CEP) (supplement to issue 2)

Kidney failure

2001 Canadian Hypertension Recommendations (Leung and Yamashita) (L) 222

[reply] (Campbell) (L) 222

Lepirudin dose recommendations for treatment of heparin-induced thrombocytopenia in patients undergoing intermittent hemodialysis (Wazny and Brackbill) (CR) 39

Knee replacement See **Arthroplasty, replacement, knee**

Lactobacillus

Effect of live lactobacilli yogurt preparation in enterally fed patients with antibiotic associated diarrhea (Yamashita) (Abs) PPC 59

Learning

Self-directed learning—Myths and challenges (Schindel) (Abs) AGM 26

Lepirudin See **Anticoagulants**

Letters

2001 Canadian Hypertension Recommendations (Leung and Yamashita) 222

[reply] (Campbell) 222

Anti-factor Xa monitoring in overweight and obese patients (Wilbur) 336

Application of personal digital assistants to an infectious diseases consult service (Ong and Tailor) 281

Combined olanzapine- and risperidone-induced diabetic ketoacidosis (Dahri and Brown) 282

Impact of collaborative drug therapy management by pharmacists (Szeto and Brown) 333

Postpartum indomethacin-associated psychosis (Lyons and Cronje) 63

Resolution of acute interstitial nephritis without steroids (Ledger and Rao) 147

Stability of mycophenolate mofetil in a 1:1 mixture of Ora-Sweet and Ora-Plus (Ensom and Decarie) 63

Levofloxacin See **Ofloxacin**



Lifestyle

The 2001 Canadian hypertension recommendations: What's new and what's not so new but is still important (Canadian Hypertension Recommendations Working Group) (PP) 46 [correction 337]

Lung diseases, obstructive

Update in COPD therapeutics (Evans) (Abs) AGM 18

Medical errors

Keeping our patients safe—A pharmacist's perspective on medical error & medication safety (Salsman) (Abs) AGM 17

Medication safety alerts (U) (PP) 52

Mistakes killing patients! / Erreurs fatales ! (MacKeigan) (E) 6 / 10

Medical informatics

Clinical pharmacist as information manager: Accessing the evidence where and when you need it (Loewen) (Abs) AGM 27

Medical oncology

Gene therapy in oncology (Pho) (Abs) PPC 44

Implementing evidence-based antiemetic guidelines in the oncology setting: Results of a 4-month prospective intervention study (Dranitsaris and Leung) (Abs) 170

Medication errors

Keeping our patients safe—A pharmacist's perspective on medical error & medication safety (Salsman) (Abs) AGM 17

Medication safety alerts (U) (PP) 52, 143, 219, 278, 330

Mistakes killing patients! / Erreurs fatales ! (MacKeigan) (E) 6 / 10

Quantifying the impact of prescription-related problems on pharmacy workload (Fok and Lo) (A) 313

Riding the waves ... team CSHP in action / Voguer la galère ... équipe SCPH en action (Mann) (EDR) 197

La SCPH se démarque encore / CSHP—Still making a difference (Poloway) (POR) 181 / 184

Medication systems, hospital

Computerized warfarin dosing (Foss and Dolovich) (Abs) PPC 61

Medication safety alerts (U) (PP) 52, 278, 330

Mistakes killing patients! / Erreurs fatales ! (MacKeigan) (E) 6 / 10

Quantifying the impact of prescription-related problems on pharmacy workload (Fok and Lo) (A) 313

Medicine, herbal

A pilot study of a possible drug interaction between *Ginkgo biloba* and warfarin (Leung and others) (Abs) 169

Meetings See **Congresses**

Mentors

Teaching and mentorship: Invaluable contributions to the profession / Enseignement et mentorat : de précieuses contributions à la profession (Tisdale) (E) 192 / 195

Meropenem See **Carbapenems**

Methadone

Methadone maintenance: What you need to know (Isaac and Kalvic) (Abs) PPC 44

Monitoring, physiologic

Application of personal digital assistants to an infectious diseases consult service (Ong and Tailor) (L) 281

Morphine

Short-term stability, accuracy, and homogeneity of morphine concentrations in syringes stored at 24°C (Seto and others) (Abs) PPC 53

Mycophenolate mofetil See **Immunosuppressive agents**

Myocardial infarction

How to evaluate pharmacoeconomic data: The example of enoxaparin in acute coronary syndromes (Pharand) (A) 114

Myocardial ischemia

Secondary prevention in ischemic heart disease: Utilization of antiplatelet agents in federal clients (Gutschli) (Abs) PPC 58

National Pharmacy Forum See **Congresses**

Nebulizers and vapourizers

Pharmacy educational initiative to decrease nebulization use in tertiary care hospital (Lummis) (Abs) PPC 52

Nephritis, interstitial

Fluoroquinolone-induced acute interstitial nephritis: Two case reports (MacAulay and others) (CR) 139

Resolution of acute interstitial nephritis without steroids (Ledger and Rao) (L) 147

Neutropenia

Invasive fungal infection: Review and update of drug management (McTaggart and Wong) (CEP) (supplement to issue 2)

Norepinephrine

Medication safety alerts (U) (PP) 330

Norfloxacin

Fluoroquinolone-induced acute interstitial nephritis: Two case reports (MacAulay and others) (CR) 139

Nurse practitioners

Pharmacists and nurse practitioners: A partnership that works (Leblanc and Merkle) (Abs) PPC 28

Nutrition

Total nutritional admixtures (Gulak) (Abs) PPC 48

Obesity

Anti-factor Xa monitoring in overweight and obese patients (Wilbur) (L) 336

Occupational health

The Workplace Safety and Insurance Board and Sunnybrook and Women's College Health Sciences Centre: A unique partnership (Weinstein and others) (Abs) PPC 54

Ofloxacin

Fluoroquinolone-induced acute interstitial nephritis: Two case reports (MacAulay and others) (CR) 139

Levofloxacin-induced bilateral Achilles tendinopathy (Connelly and others) (CR) 212

Olanzapine See **Dibenzothiazepines**

Omeprazole

Audit of IV pantoprazole: Patterns of use and compliance with guidelines (Cornish and others) (A) 20

Medication safety alerts (U) (PP) 219

Organ transplantation

A medication teaching video series for organ transplant recipients (Denesyk) (Abs) 171

Ortho Distinguished Service Award See **Awards and prizes**



Oseltamivir

Use of oseltamivir during influenza outbreaks in provincial nursing homes, 1999–2000 (Bowles) (Abs) 171

Outcome assessment (health care)

Antibiotic use in a family practice setting (Karakashian and others) (A) 198

Goal attainment scaling in the provision of pharmaceutical care to hospitalized patients with cardiovascular disease: A pilot study (Nieuwstraten and others) (A) 262

Impact of collaborative drug therapy management by pharmacists (Szeto and Brown) (L) 333

Outpatient treatment See **Ambulatory care****Overdose**

Lepirudin dose recommendations for treatment of heparin-induced thrombocytopenia in patients undergoing intermittent hemodialysis (Wazny and Brackbill) (CR) 39

Oxycodone

Stability of oxycodone hydrochloride for injection in dextrose and saline solutions (Turnbull and others) (A) 272

Pantoprazole See **Proton pump****Parenteral nutrition, total**

Total parenteral nutrition practices in Canadian neonatal and pediatric care units: Results of a survey (Wlodarczyk and others) (A) 254

Partial thromboplastin time

Lepirudin dose recommendations for treatment of heparin-induced thrombocytopenia in patients undergoing intermittent hemodialysis (Wazny and Brackbill) (CR) 39

Patents

Who owns your genes? (Walker) (FC) 248

Patient care

Patient assessment: The art & science of it (Dillon) (Abs) AGM 23

Patient discharge

Assessment of a seamless care prescription/discharge note form (Rogers and others) (Abs) PPC 57

Characterizing patient discharge counselling activities performed by hospital pharmacists (Curran and others) (Abs) AGM 34

Computer-formatted discharge medication chart (Jackson and Awdishu) (Abs) PPC 58

Medication safety alerts (U) (PP) 143

Seamless care: Evaluating the impact of a new discharge prescription form (Connelly and others) (Abs) PPC 60

Patient education

Development of a pharmacist-managed preventive medication assessment program in a family physician office setting: The medication checkup (Kennie and Bajcar) (A) 320

Impact of pharmaceutical care on dialysis patients' knowledge (Wlodarczyk and others) (Abs) PPC 57

Medication safety alerts (U) (PP) 143

A medication teaching video series for organ transplant recipients (Denesyk) (Abs) 171

Pharmacists improving patient outcomes in congestive heart failure: Results of the REACT Study (Tsuyuki) (Abs) PPC 32

A pilot study on the effects of a multidisciplinary support group program in improving the adaptive life skills of heart failure patients (Chan and others) (Abs) AGM 33

Patient monitoring See **Monitoring, physiologic****Patient outcome assessment** See **Outcome assessment (health care)****Patient participation**

Goal attainment scaling in the provision of pharmaceutical care to hospitalized patients with cardiovascular disease: A pilot study (Nieuwstraten and others) (A) 262

Peer review, research

Peer review and the publication process (Walker) (Abs) PPC 37

Peptic ulcer

Audit of IV pantoprazole: Patterns of use and compliance with guidelines (Cornish and others) (A) 20

Pharmaceutical services

Developing a collaborative working group to advance the role of pharmacists in the care of patients with cardiovascular disease (Canadian Cardiovascular Pharmacists Network) (Abs) PPC 51

Developing a collaborative working group to advance the role of pharmacists in the care of patients with cardiovascular disease (Gordon) (Abs) AGM 30

Development of a pharmacist-managed preventive medication assessment program in a family physician office setting: The medication checkup (Kennie and Bajcar) (A) 320

Evaluating the impact of pharmacists' independent interventions on patient care (Brown and Szeto) (Abs) PPC 56

Examining the role of pharmacist in multidisciplinary diabetes management (Leung and others) (Abs) PPC 51

Impact of collaborative drug therapy management by pharmacists (Szeto and Brown) (L) 333

An information paper on pharmacist prescribing within a health care facility (Pearson and others) (IP) 56

Le pharmacien prescripteur : à la recherche de l'excellence des soins aux patients / Pharmacist prescribing: Striving for excellence in patient care (Gray) (POR) 90 / 92

Prescriptive authority for pharmacists: Where are we? Where are we going? (Yuksel and Pearson) (Abs) PPC 30

Professional boundaries / Les limites de la profession (Dupuis) (E) 98 / 102

Quality improvement initiative for pharmacist-assisted warfarin dosing: Implementation and evaluation of a new protocol (To and Jackevicius) (A) 105

Riding the waves ... team CSHP in action / Voguer la galère ... équipe SCPH en action (Mann) (EDR) 197

The role of the pharmacist in an outpatient cardiac clinic (CARE—Cardiac Assessment, Risk reduction and Education service) (Bhajan-Mathur and others) (Abs) PPC 58

La SCPH se démarque encore / CSHP—Still making a difference (Poloway) (POR) 181 / 184

Statement on pharmacist prescribing (Pearson and others) (S) 55



Venous thrombosis and the pharmacist / La thrombose veineuse et le pharmacien (Bartle and Geerts) (E) 302 / 304

Pharmacist shortage See **Health manpower**

Pharmacists

Educational needs assessment for international pharmacy graduates (Austin and others) (Abs) PPC 55

Pharmacists' aides

Clinical pharmacy technician—Reasoning and role (Brown and McKenzie) (Abs) AGM 32

Evaluation of prescribing competence among physician assistants in the Canadian Forces (Vaillancourt and others) (Abs) PPC 55

Opportunities for pharmacy technicians: Pushing the envelope without spilling the contents (Ensom and others) (Abs) AGM 21

Optimizing and creating roles for technicians (Colquhoun) (Abs) PPC 43

Riding the waves ... team CSHP in action / Voguer la galère ... équipe SCPH en action (Mann) (EDR) 197

La SCPH se démarque encore / CSHP—Still making a difference (Poloway) (POR) 181 / 184

Pharmacist's role See **Pharmaceutical services**

Pharmacoeconomics See **Economics, pharmaceutical**

Pharmacogenetics

Brave new world? (Walker) (FC) 300

Pharmacogenetics: The therapeutic drug monitoring of the future (Ensom) (Abs) PPC 25

Pharmacogenomics (Walker) (FC) 188

Pharmacy administration

Do Canada's hospital pharmacy management personnel have the skills they need? Results from a national survey (MacKinnon) (Abs) 170

York Central Hospital announces new Director of Pharmacy Services (SN) 350

Pharmacy technicians See **Pharmacists' aides**

Phenylephrine

Medication safety alerts (U) (PP) 330

Pheochromocytoma

The 2001 Canadian hypertension recommendations: What's new and what's not so new but is still important (Canadian Hypertension Recommendations Working Group) (PP) 46 [correction 337]

Physician order entry systems See **Medication systems, hospital**

Physician's practice patterns

A systematic review of the literature on profiling physicians to promote appropriate, cost-effective prescribing (Cooke and others) (Abs) AGM 33

Total parenteral nutrition practices in Canadian neonatal and pediatric care units: Results of a survey (Wlodarczyk and others) (A) 254

Planning techniques

Using a logic model in planning and evaluating programs and services (Marshman) (Abs) PPC 32

Platelet aggregation inhibitors

Secondary prevention in ischemic heart disease: Utilization of antiplatelet agents in federal clients (Gutsch) (Abs) PPC 58

Polyenes

Invasive fungal infection: Review and update of drug management (McTaggart and Wong) (CEP) (supplement to issue 2)

Postnatal care

Postpartum indomethacin-associated psychosis (Lyons and Cronje) (L) 63

Potassium chloride

Medication safety alerts (U) (PP) 219, 278

Practice guidelines

Antibiotic use in a family practice setting (Karakashian and others) (A) 198

Implementing evidence-based antiemetic guidelines in the oncology setting: Results of a 4-month prospective intervention study (Dranitsaris and Leung) (Abs) 170

Total parenteral nutrition practices in Canadian neonatal and pediatric care units: Results of a survey (Wlodarczyk and others) (A) 254

Prednisone

Resolution of acute interstitial nephritis without steroids (Ledger and Rao) (L) 147

Prescriptions, drug

Impact d'une intervention visant à améliorer la conformité des ordonnances de médicaments à la règle d'émission au sein d'un établissement de santé (Bussièrès and Lebel) (Abs) 169

Impact of collaborative drug therapy management by pharmacists (Szeto and Brown) (L) 333

An information paper on pharmacist prescribing within a health care facility (Pearson and others) (IP) 56

Le pharmacien prescripteur : à la recherche de l'excellence des soins aux patients / Pharmacist prescribing: Striving for excellence in patient care (Gray) (POR) 90 / 92

Quantifying the impact of prescription-related problems on pharmacy workload (Fok and Lo) (A) 313

Statement on pharmacist prescribing (Pearson and others) (S) 55

Primary health care

Development of a pharmacist-managed preventive medication assessment program in a family physician office setting: The medication checkup (Kennie and Bajcar) (A) 320

Professional Practice Conference See **Congresses**

Program development

Development of a pharmacist-managed preventive medication assessment program in a family physician office setting: The medication checkup (Kennie and Bajcar) (A) 320

Program evaluation

Development of a pharmacist-managed preventive medication assessment program in a family physician office setting: The medication checkup (Kennie and Bajcar) (A) 320

Proton pump

Audit of IV pantoprazole: Patterns of use and compliance with guidelines (Cornish and others) (A) 20

Evaluation of usage of IV pantoprazole in a community hospital (Lakhani) (Abs) AGM 29



Psychosis, substance-induced

Postpartum indomethacin-associated psychosis (Lyons and Cronje) (L) 63

Publishing

Bracing for waves, smooth sailing ahead / Prêts à voguer, mer calme à l'horizon (Mann) (EDR) 14

How to turn a poster or abstract into a full-length manuscript (Ensom) (Abs) AGM 18

Pulmonary embolism

An economic comparison of enoxaparin and warfarin in the prevention of deep vein thrombosis after hip and knee replacement (Friesen and others) (A) 128

Quality of health care

Impact of collaborative drug therapy management by pharmacists (Szeto and Brown) (L) 333

Medication safety alerts (U) (PP) 52, 278

Mistakes killing patients! / Erreurs fatales ! (MacKeigan) (E) 6 / 10

Quality improvement initiative for pharmacist-assisted warfarin dosing: Implementation and evaluation of a new protocol (To and Jackevicius) (A) 105

Riding the waves ... team CSHP in action / Voguer la galère ... équipe SCPH en action (Mann) (EDR) 197

Venous thrombosis and the pharmacist / La thrombose veineuse et le pharmacien (Bartle and Geerts) (E) 302 / 304

Ramipril

Migrating angioedema possibly related to angiotensin-converting enzyme inhibitor (Newby and Thongthai) (CR) 136

Renal artery obstruction

2001 Canadian Hypertension Recommendations (Leung and Yamashita) (L) 222
[reply] (Campbell) (L) 222

Research

Research as an avenue to invigorate your practice? / La recherche : un souffle nouveau à la pratique? (Ensom) (E) 250 / 252

Striving for excellence ... with great success! / À la recherche de l'excellence : un véritable succès ! (Mann) (EDR) 104

Research support

Research as an avenue to invigorate your practice? / La recherche : un souffle nouveau à la pratique? (Ensom) (E) 250 / 252

Rimantadine

Meta-analysis of amantadine and rimantadine for prophylaxis and treatment of influenza A virus infection (Marra and others) (Abs) PPC 49

Risk management

Mistakes killing patients! / Erreurs fatales ! (MacKeigan) (E) 6 / 10

Risperidone

Combined olanzapine- and risperidone-induced diabetic ketoacidosis (Dahri and Brown) (L) 282

Seamless care See **Continuity of patient care**

Self-medication

Development of a tool to assess the geriatric patient's ability for self-medication (Flanagan and MacLeod) (Abs) 171

Sepsis

Issues in critical care (Chant and Yamashita) (Abs) PPC 41

Serotonin uptake inhibitors

Optimizing the treatment of depression: Strategies for augmenting and combining antidepressants (Zerjav) (Abs) PPC 27

Shock

The use of inotropes and vasopressors in the provision of pharmaceutical care to the shock patient (Brown) (Abs) PPC 39

Shock, septic

Issues in critical care (Chant and Yamashita) (Abs) PPC 41
Re-addressing the challenges of septic shock: A review of anticoagulation therapies (Burry) (Abs) PPC 38

Smoking cessation

Smoking cessation program for hospitalized vascular patients (Kwok and others) (Abs) PPC 58

Sterilization

Microbiological validation of sterile preparation procedures in a pharmacy department (Bussières) (Abs) 172

Stroke See **Cerebrovascular disorders**

Substance-related disorders

What's the buzz? Identifying local patterns of drug abuse (Webb and Kent) (Abs) AGM 32

Succinylcholine

Medication safety alerts (U) (PP) 219

Suspensions

Stability of mycophenolate mofetil in a 1:1 mixture of Ora-Sweet and Ora-Plus (Ensom and Decarie) (L) 63

Teaching

Teaching and mentorship: Invaluable contributions to the profession / Enseignement et mentorat : de précieuses contributions à la profession (Tisdale) (E) 192 / 195

Tedelparin

Anti-factor Xa monitoring in overweight and obese patients (Wilbur) (L) 336

Arguments against monitoring levels of anti-factor Xa in conjunction with low-molecular-weight heparin therapy (Rosenbloom and Ginsberg) (A) 15

Telehealth Ontario See **Information services**

Tendinitis

Levofloxacin-induced bilateral Achilles tendinopathy (Connelly and others) (CR) 212

Tetracaine

Randomized, controlled trial assessing the efficacy of the topical amethocaine gel to reduce pain in infants undergoing heel pricks (Patel and others) (Abs) PPC 48

Therapeutic equivalency

Formulary considerations related to warfarin interchangeability (Sawoniak and others) (PP) 215

Thoracic surgery

Enhancement of medication utilization for patients undergoing cardiac surgery (Semchuk) (Abs) PPC 48

Thrombocytopenia

Lepirudin dose recommendations for treatment of heparin-induced thrombocytopenia in patients undergoing intermittent hemodialysis (Wazny and Brackbill) (CR) 39

Pharmacy-based heparin-induced thrombocytopenia surveillance program for heart valve replacement patients (Paradiso-Hardy and others) (Abs) 169, PPC 49

Thromboembolism

Anti-factor Xa monitoring in overweight and obese patients (Wilbur) (L) 336

Venous thrombosis and the pharmacist / La thrombose veineuse et le pharmacien (Bartle and Geerts) (E) 302 / 304

Titration See **Titrimetry**

Titrimetry

Medication safety alerts (U) (PP) 330

Torsades de pointes

Be still my quivering heart: Culprits and mechanisms of drug-induced arrhythmias (Tisdale) (Abs) PPC 33

Transient ischemic attack See **Cerebral ischemia, transient**

Trimethoprim-sulfamethoxazole combination

Stability of trimethoprim in admixtures of trimethoprim-sulfamethoxazole prepared in polyvinylchloride bags and glass bottles (Curtis and Edwards) (A) 207

United States

An information paper on pharmacist prescribing within a health care facility (Pearson and others) (IP) 56

Medication safety alerts (U) (PP) 52, 219

Professional boundaries / Les limites de la profession (Dupuis) (E) 98 / 102

Valacyclovir See **Acyclovir**

Valerian

Valerianic acids content of commercially available valerian preparations (Draves and others) (Abs) PPC 50

Vancomycin

Appropriate use of vancomycin at the Queen Elizabeth II Health Sciences (QEII HSC) and opportunity for switch from IV to oral therapy (LeBlanc and others) (Abs) PPC 53

Assessment of empiric vancomycin regimen in neonates (Newby) (Abs) PPC 49

A comparison of 2 dosage regimens of intravenous vancomycin in hemodialysis patients (Harder and others) (Abs) 172

Vasoconstrictor agents

The use of inotropes and vasopressors in the provision of pharmaceutical care to the shock patient (Brown) (Abs) PPC 39

Vasopressors See **Vasoconstrictor agents**

Venous thrombosis

Arguments against monitoring levels of anti-factor Xa in conjunction with low-molecular-weight heparin therapy (Rosenbloom and Ginsberg) (A) 15

An economic comparison of enoxaparin and warfarin in the prevention of deep vein thrombosis after hip and knee replacement (Friesen and others) (A) 128

Venous thrombosis and the pharmacist / La thrombose veineuse et le pharmacien (Bartle and Geerts) (E) 302 / 304

Vestibular function tests

Pharmacist utilization of the DIE test to assess aminoglycoside vestibulotoxicity (Shalansky and others) (Abs) 170

Vincristine

Medication safety alerts (U) (PP) 219

Voluntary workers

Président élu ? Qui ? Moi ? / President Elect—who, me? (Johnson) (POR) 295 / 296

Voriconazole See **Azoles**

Warfarin

An economic comparison of enoxaparin and warfarin in the prevention of deep vein thrombosis after hip and knee replacement (Friesen and others) (A) 128

Formulary considerations related to warfarin interchangeability (Sawoniak and others) (PP) 215

Highlighting 10 years' experience with a pharmacist-directed warfarin nomogram program at a community hospital (Pao and others) (Abs) PPC 48

A pilot study of a possible drug interaction between *Ginkgo biloba* and warfarin (Leung and others) (Abs) 169

Quality improvement initiative for pharmacist-assisted warfarin dosing: Implementation and evaluation of a new protocol (To and Jackevicius) (A) 105

Weight loss

Winning strategies in the management of obesity (Berkoff) (Abs) PPC 30

Workload

Quantifying the impact of prescription-related problems on pharmacy workload (Fok and Lo) (A) 313



Author Index

- Abraham P** See **Salama SE** Jt Auth
Adams AJ See **Karakashian S** Jt Auth
Ashton T See **Tsuyuki RT** Jt Auth
Austin Z, Wichman K, Rocchi Dean M, Croteau D, Schillemore C
Educational needs assessment for international pharmacy graduates (Abs) PPC 55
Awdishu L See **Jackson L** Jt Auth
- Bachynsky J** See **Friesen E** Jt Auth
Bain D See **Weinstein S** Jt Auth
Bajcar J See **Kennie N** Jt Auth
Balen RM
Using personal digital assistants (PDAs) in pharmacy practice: An overview for beginners and insights for the advanced user (Abs) PPC 26
See also **Curran R** Jt Auth
Banerjee A See **Salama SE** Jt Auth
Barbiero K See **Pao D** Jt Auth
Bartle WR See **Paradiso-Hardy F** Jt Auth
Bartle WR, Geerts W
Venous thrombosis and the pharmacist / La thrombose veineuse et le pharmacien (E) 302 / 304
Bates D
Valacyclovir neurotoxicity: Two case reports and a review of the literature (A) 123
Bath J See **Seto W** Jt Auth
Bayliff CD See **Connelly S** Jt Auth; **Knippel JJ** Jt Auth; **Woodworth S** Jt Auth; **Connelly S** Jt Auth; **MacAulay S** Jt Auth
Bayliff CD, Julien J-Y, Twaites L, Rowe M
CSHP Fellows—Consistent contributors to our profession (Abs) PPC 63
Beauchamp G See **Chan J** Jt Auth
Bell H See **Chan J** Jt Auth
Berkoff F
Winning strategies in the management of obesity (Abs) PPC 30
Berry S See **Pao D** Jt Auth
Bhajan-Mathur S
Case report: Infliximab (Remicade®) induced herpes zoster (Abs) PPC 60
See also **Pao D** Jt Auth
Bhajan-Mathur S, Kwan A, Cheung T
The role of the pharmacist in an outpatient cardiac clinic (CARE—Cardiac Assessment, Risk reduction and Education service) (Abs) PPC 58
Bielech M See **Turnbull K** Jt Auth
Blatman B See **Pao D** Jt Auth
Blocka J See **Nguyen A** Jt Auth
Boddam R See **Gutschi LM** Jt Auth
Bombassaro AM See **Karakashian S** Jt Auth
Bonnici A See **Pradhan R** Jt Auth
Boucher M, Rodger M, Johnson JA, Tierney M
Shifting from inpatient to outpatient treatment of deep vein thrombosis in a tertiary care centre: A cost-minimization analysis (Abs) PPC 55
- Bowles SK**
Update on the management of patients with cognitive impairment (Abs) PPC 31
Use of oseltamivir during influenza outbreaks in provincial nursing homes, 1999–2000 (Abs) 171
Brackbill ML See **Wazny LD** Jt Auth
Brown G
The use of inotropes and vasopressors in the provision of pharmaceutical care to the shock patient (Abs) PPC 39
See also **Dahri K** Jt Auth; **EnsomRJ** Jt Auth; **Szeto J** Jt Auth
Brown G, McKenzie L
Clinical pharmacy technician—Reasoning and role (Abs) AGM 32
Brown G, Szeto J
Evaluating the impact of pharmacists' independent interventions on patient care (Abs) PPC 56
The prevalence and avoidability of drug-induced admissions to an intensive care unit (Abs) PPC 52
Brunne A See **Chan J** Jt Auth
Bucci C See **Paradiso-Hardy F** Jt Auth
Bungard TJ See **Tsuyuki RT** Jt Auth
Bunting BJ See **Knippel JJ** Jt Auth
Burry L
Re-addressing the challenges of septic shock: A review of anticoagulation therapies (Abs) PPC 38
Bussi eres J-F
Microbiological validation of sterile preparation procedures in a pharmacy department (Abs) 172
Bussi eres J-F, Lebel D
Exploration et mod ele d'analyse de ratios de co ts de m dicaments par indicateurs de volumes d'activit es en  tablissement de sant  (Abs) 169
Impact d'une intervention visant   am liorer la conformit  des ordonnances de m dicaments   la r gle d' mission au sein d'un  tablissement de sant  (Abs) 169
Busto UE See **Draves AH** Jt Auth
- Campbell NRC**
2001 Canadian Hypertension Recommendations [reply] (L) 222
Canadian Cardiovascular Pharmacists Network
Developing a collaborative working group to advance the role of pharmacists in the care of patients with cardiovascular disease (Abs) PPC 51
Canadian Hypertension Recommendations Working Group
The 2001 Canadian hypertension recommendations: What's new and what's not so new but is still important (PP) 46 [correction 337]
Card D See **Pearson G** Jt Auth
Cardinal P See **Fairbairn J** Jt Auth
Carr D See **Shalansky K** Jt Auth
Cepuch CA
Thinking beyond our borders: Global issues with medications (Abs) PPC 45
Chan J See **Walker SE** Jt Auth



- Chan J, Mohamed S, Neil Pollinger D, Bell H, Brunne A, Trentowsky S, Glofcheski K, Beauchamp G, Nolan R, Jong P**
A pilot study on the effects of a multidisciplinary support group program in improving the adaptive life skills of heart failure patients (Abs) AGM 33
- Chang B** See **Halapy H** Jt Auth
- Chant C, Yamashita S**
Issues in critical care (Abs) PPC 41
- Chase H** See **Leung G** Jt Auth; **Nieuwstraten C** Jt Auth
- Cheung T** See **Bhajan-Mathur S** Jt Auth; **Pao D** Jt Auth
- Chin T** See **Pearson G** Jt Auth
- Cohen E** See **Shamiss Y** Jt Auth
- Cole DL**
Breast cancer update (Abs) AGM 19
- Colquhoun M**
Optimizing and creating roles for technicians (Abs) PPC 43
- Connelly S, Bayliff C, Mehta S**
Levofloxacin-induced Achilles tendinopathy (CR) 212
- Connelly S, Yoong D, Martin J, Zarnke K, Bayliff CD, Delamere K**
Seamless care: Evaluating the impact of a new discharge prescription form (Abs) PPC 60
- Cooke C**
Applying the WHO ATC/DDD system of drug classification in drug utilization: The promise and the pitfalls (Abs) AGM 24
- Cooke C, Sketris I, Frail D**
A systematic review of the literature on profiling physicians to promote appropriate, cost-effective prescribing (Abs) AGM 33
- Cornish P, Papastergiou J, Saibil F**
Audit of IV pantoprazole: Patterns of use and compliance with guidelines (A) 20
- Cronje JS** See **Lyons B** Jt Auth
- Croteau D** See **Austin Z** Jt Auth
- Crown N, Virani A**
The impact of a clinical pharmacist on patient and economic outcomes on the child and adolescent mental health unit at the IWK Health Centre (Abs) PPC 56
- Curran R, Dossa A, Balen R, Wilbur K**
Characterizing patient discharge counselling activities performed by hospital pharmacists (Abs) AGM 34
- Curtis JM, Edwards DJ**
Stability of trimethoprim in admixtures of trimethoprim-sulfamethoxazole prepared in polyvinylchloride bags and glass bottles (A) 207
- Czerniawski B** See **Patel A** Jt Auth
- Dahri K, Brown G**
Combined olanzapine- and risperidone-induced diabetic Ketoacidosis (L) 282
- Daws D, Willis GA, Lepik KJ, Kent DA, Gorman S**
Coordinated antidote distribution—A poison control centre model (Abs) AGM 29
- Decarie D** See **Ensom MHH** Jt Auth
- Dekker A**
Pediatric immunizations: New agents and current controversies (Abs) PPC 43
- Delamere K** See **Connelly S** Jt Auth
- Denesyk K**
A medication teaching video series for organ transplant recipients (Abs) 171
- Derry T** See **Leung F** Jt Auth
- Dillon EC**
Patient assessment: The art & science of it (Abs) AGM 23
- Dolovich L** See **Foss A** Jt Auth; **Lee J** Jt Auth; **Leung G** Jt Auth; **Nieuwstraten C** Jt Auth
- Donnelly RF**
Chemical stability of dimenhydrinate in minibags and polypropylene syringes (A) 307
- Dossa A** See **Curran R** Jt Auth
- Dranitsaris G, Leung P**
Implementing evidence-based antiemetic guidelines in the oncology setting: Results of a 4-month prospective intervention study (Abs) 170
- Draves AH, Glass J, Walker SE, Busto UE**
Valerenic acids content of commercially available valerian preparations (Abs) PPC 50
- Dresser L** See **LeBlanc J** Jt Auth
- Drynan J** See **Yamashita S** Jt Auth
- Dupuis LL**
Professional boundaries / Les limites de la profession (E) 98 / 102
- Dzavik V** See **Pearson GJ** Jt Auth
- Edwards DJ** See **Curtis JM** Jt Auth
- Edwards M**
Development of a gentamicin protocol for a community hospital (Abs) AGM 33
- Ensom MHH**
How to turn a poster or abstract into a full-length manuscript (Abs) AGM 18
Pharmacogenetics: The therapeutic drug monitoring of the future (Abs) PPC 25
Research as an avenue to invigorate your practice? / La recherche : un souffle nouveau à la pratique? (E) 250 / 252
- Ensom MHH, Decarie D**
Stability of mycophenolate mofetil in a 1:1 mixture of Ora-Sweet and Ora-Plus (L) 63
- Ensom RJ, Brown G, Quinn I**
Opportunities for pharmacy technicians: Pushing the envelope without spilling the contents (Abs) AGM 21
- Evans B**
Update in COPD therapeutics (Abs) AGM 18
- Fairbairn J, Gillison M, McDonald K, Zvonar R, Cardinal P**
Clonidine use in intensive care unit patients: A retrospective analysis (Abs) PPC 56
- Fernandes O, Wong G**
Assessing and managing acid-base disorders in your patients (Abs) PPC 41
- Flanagan P, MacLeod D**
Development of a tool to assess the geriatric patient's ability for self-medication (Abs) 171



Fok M, Lo A

Quantifying the impact of prescription-related problems on pharmacy workload (A) 313

Forward K See **Muise T** Jt Auth

Foss A, Dolovich L

Computerized warfarin dosing (Abs) PPC 61

Fradette M See **Tsuyuki RT** Jt Auth

Frail D See **Cooke C** Jt Auth

Francis GA See **Pearson GJ** Jt Auth

Friesen E, Lier D, Bachynsky J, Jacobs P

An economic comparison of enoxaparin and warfarin in the prevention of deep vein thrombosis after hip and knee replacement (A) 128

Frighetto L See **Jewesson P** Jt Auth

Fyke K

Health care reform (Abs) PPC 34

Gardner DM

Antipsychotic medicines: Deconstructing manufactured beliefs (Abs) PPC 26

See also **Horwood S** Jt Auth

Gaucher M

La SCPH appelée à l'action ! / CSHP—Called to action! (POR) 243 / 244

Geerts W See **Bartle WR** Jt Auth

George CFP See **Woodworth S** Jt Auth

George K See **Paradiso-Hardy F** Jt Auth

Gillis J See **McLean W** Jt Auth

Gillison M See **Fairbairn J** Jt Auth

Gin K See **Leung VWY** Jt Auth

Ginsberg JS See **Rosenbloom D** Jt Auth

Glass J See **Draves AH** Jt Auth

Glofcheski K See **Chan J** Jt Auth

Gordon W

Developing a collaborative working group to advance the role of pharmacists in the care of patients with cardiovascular disease (Abs) AGM 30

See also **Tsuyuki RT** Jt Auth

Gorman S See **Daws D** Jt Auth

Gray M

AGM 2002: A time to review, a time to renew / AGA 2002 :

Un vent de réflexion, un vent de renouveau (POR) 356 / 358

Le pharmacien prescripteur : à la recherche de l'excellence des soins aux patients / Pharmacist prescribing: Striving for excellence in patient care (POR) 90 / 92

See also **Pearson G** Jt Auth

Gray S See **Patel A** Jt Auth

Guillemette M, Vaillancourt R, Gutsch M

The impact of treatment with antidepressant (AD) drug therapy on the utilization of proton pump inhibitors (PPI) or histamine 2 antagonists (H2 blockers) (Abs) PPC 53

Gulak AD

Total nutritional admixtures (Abs) PPC 48

Gutsch M See **Guillemette M** Jt Auth; **Vaillancourt R** Jt Auth

Gutsch M, Vaillancourt R, Boddam R

Drug use evaluation of antidepressant (AD) drugs in the Canadian Forces (Abs) PPC 50

Gutsch M

Secondary prevention in ischemic heart disease: Utilization of antiplatelet agents in federal clients (Abs) PPC 58

Haase D See **Muise T** Jt Auth

Halapy H, Chang B

A systematic review of erectile dysfunction medication literature in patients with diabetes (Abs) PPC 52

Halasi S

Pharmaceutical care pilot project: Provision of service in a community pharmacy using resources and knowledge of a drug information call centre (Abs) PPC 54

Hales B See **Seto W** Jt Auth

Harder C, Shalansky S, Jung J, Lee A

A comparison of 2 dosage regimens of intravenous vancomycin in hemodialysis patients (Abs) 172

Hawbold J See **Pearson G** Jt Auth

Heffer M See **Wong C** Jt Auth

Hertz S See **Wichman K** Jt Auth

Hewitt G See **Salama SE** Jt Auth

Hill DS

Entry level degree in Canada—PharmD or BSc (Abs) AGM 26

Hiltz N See **Muise T** Jt Auth

Hogg A See **Wong C** Jt Auth

Holness L See **Weinstein S** Jt Auth

Horwood S, Pierce S, Slayter K, Gardner D, MacDonald S, Johnston BL

Evaluation of risk factors for clostridium difficile-associated diarrhea at the Queen Elizabeth II Health Sciences Centre (Abs) PPC 57

Hsu T See **Pao D** Jt Auth

Hussain Z See **Karakashian S** Jt Auth

Hutchinson J

The importance of measuring antibiotic consumption in the fight against antibiotic resistance—Focus on ATC/DDD methodology (Abs) AGM 24

Hyland S See **U D** Jt Auth

Ikuta R See **Tsuyuki RT** Jt Auth

Isaac P, Kalvic A

Methadone maintenance: What you need to know (Abs) PPC 44

Jackevicius C

Workshop on economic analysis (Abs) AGM 22

See also **Pearson G** Jt Auth; **To E** Jt Auth

Jackson L, Awdishu L

Computer-formatted discharge medication chart (Abs) PPC 58

Jacobs P See **Friesen E** Jt Auth

Jelincic V See **U D** Jt Auth

Jetha S See **Pao D** Jt Auth

Jewesson P, Wai AO, Marra CA, Frighetto L

Patient preferences in a outpatient parenteral antibiotic therapy program (Abs) 171

- Johnson JA** See **Boucher M** Jt Auth; **Tsuyuki RT** Jt Auth
Johnson N
 New medications—Paying the bill (Abs) AGM 20
 Président élu ? Qui ? Moi ? / President Elect—who me?
 (POR) 295 / 296
- Johnston BL** See **Horwood S** Jt Auth; **LeBlanc J** Jt Auth
Jong P See **Chan J** Jt Auth
Julien J-Y See **Bayliff CD** Jt Auth
Jung J See **Harder C** Jt Auth
- Karakashian S, Hussain Z, McSherry JA, Adams AJ, Lent B, Wetmore SJ, Bombassaro AM**
 Antibiotic use in a family practice setting (A) 198
Karra K See **Walker SE** Jt Auth
Kennie N, Bajcar J
 Development of a pharmacist-managed preventive medication assessment program in a family physician office setting: The medication checkup (A) 320
Kent DA See **Daws D** Jt Auth; **Webb JM** Jt Auth
Khaykin Y See **Shamiss Y** Jt Auth
Knippel JJ, Bayliff CD, Bunting BJ, Mehta S
 Clinical deterioration secondary to epoprostenol infusion interruption (Abs) PPC 56
Kornder J See **Tsuyuki RT** Jt Auth
Kwan A See **Bhajan-Mathur S** Jt Auth; **Pao D** Jt Auth
Kwok L, Song K, Madden S
 Smoking cessation program for hospitalized vascular patients (Abs) PPC 58
Kwon JJH See **Wichman K** Jt Auth
- Lakhani A**
 Evaluation of usage of IV pantoprazole in a community hospital (Abs) AGM 29
Law S See **Turnbull K** Jt Auth; **Walker SE** Jt Auth
Lebel D See **Bussièrès J-F** Jt Auth
LeBlanc J, Slayter K, Johnston BL, McNeil SA, Dresser L
 Appropriate use of vancomycin at the Queen Elizabeth II Health Sciences (QEII HSC) and opportunity for switch from IV to oral therapy (Abs) PPC 53
Leblanc K, Merkley J
 Pharmacists and nurse practitioners: A partnership that works (Abs) PPC 28
Ledger S, Rao M
 Resolution of acute interstitial nephritis without steroids (L) 147
Lee A See **Harder C** Jt Auth
Lee J, Dolovich L
 A qualitative systematic review of the effects of various education strategies on pharmacists (Abs) PPC 53
Lee M See **Pao D** Jt Auth
Lefebvre P See **Pradhan R** Jt Auth
Lent B See **Karakashian S** Jt Auth
Leob M See **Salama SE** Jt Auth
Lepik KJ See **Daws D** Jt Auth
Leson CL See **Wlodarczyk K** Jt Auth
Leung F, Derry T, Vecchiarelli D
 Examining the role of pharmacist in multidisciplinary diabetes mellitus (Abs) PPC 51
- Leung G, Dolovich L, Chase H**
 A pilot study of a possible drug interaction between *Ginkgo biloba* and warfarin (Abs) 169
Leung L, Yamashita S
 2001 Canadian Hypertension Recommendations (L) 222
Leung P See **Dranitsaris G** Jt Auth
Leung VWY, Sunderji R, Zed PJ, Gin K
 Switching from abciximab to eptifibatide for percutaneous coronary interventions: A local analysis (SWAP study) (Abs) AGM 34
Lier D See **Friesen E** Jt Auth
Lo A See **Fok M** Jt Auth
Loewen PS
 Clinical pharmacist as information manager: Accessing the evidence where and when you need it (Abs) AGM 27
Louie S See **Nguyen A** Jt Auth
Lui E See **Patel A** Jt Auth
Lummis H
 Pharmacy educational initiative to decrease nebulization use in tertiary care hospital (Abs) PPC 52
Lyons B, Cronje JS
 Postpartum indomethacin-associated psychosis (L) 63
- Ma J** See **Vaillancourt R** Jt Auth
MacAulay S, Bayliff C, Mehta S
 Fluoroquinolone-induced acute interstitial nephritis: Two case reports (CR) 139
MacAulay S, Martin J
 Amphotericin B: A meta-analysis of lipid versus conventional formulations (Abs) PPC 60
MacDonald S See **Horwood S** Jt Auth
MacKay E See **Tsuyuki RT** Jt Auth
MacKeigan L
 Mistakes killing patients! / Erreurs fatales ! (E) 6 / 10
MacKinnon N
 Do Canada's hospital pharmacy management personnel have the skills they need? Results from a national survey (Abs) 170
 See also **Nickerson A** Jt Auth
MacLeod D See **Flanagan P** Jt Auth
Madan M See **Shamiss Y** Jt Auth
Madden S See **Kwok L** Jt Auth
Madorin P See **Paradiso-Hardy F** Jt Auth
Makowsky MJ See **Wlodarczyk K** Jt Auth
Mallinson A See **Shalansky K** Jt Auth
Mann JL
 Bracing for waves, smooth sailing ahead / Prêts à voguer, mer calme à l'horizon (EDR) 14
 Riding the waves ... team CSHP in action / Voguer la galère ... équipe SCPH en action (EDR) 197
 Striving for excellence ... with great success! / À la recherche de l'excellence : un véritable succès ! (EDR) 104
Manyari DE See **Tsuyuki RT** Jt Auth
Manzano C See **Pao D** Jt Auth
Marra CA See **Jewesson P** Jt Auth; **Marra F** Jt Auth
Marra F
 Policies and planning issues around bioterrorism (Abs) AGM 25
 See also **Shalansky K** Jt Auth



- Marra F, Marra CA, Stiver HG**
Meta-analysis of amantadine and rimantadine for prophylaxis and treatment of influenza A virus infection (Abs) PPC 49
- Marshman JA**
Using a logic model in planning and evaluating programs and services (Abs) PPC 32
- Martin J** See **Connelly S** Jt Auth; **MacAulay S** Jt Auth
- Mathew M** See **Seto W** Jt Auth
- McClure M** See **Nguyen A** Jt Auth
- McCormick JP**
Thinking outside the box—Challenging dogma (Abs) AGM 17
- McCrea P** See **Nguyen A** Jt Auth
- McDonald K** See **Fairbairn J** Jt Auth
- McKenzie L** See **Brown G** Jt Auth
- McLean W** See **Rogers K** Jt Auth
- McLean W, Gillis J, Waller R**
How more care can cost less in B.C. asthma patients (Abs) AGM 32
- McLeish N** See **Salama SE** Jt Auth
- McNeil SA** See **LeBlanc J** Jt Auth
- McSherry JA** See **Karakashian S** Jt Auth
- McTaggart B, Wong G**
Invasive fungal infection: Review and update of drug management (CEP) (supplement to issue 2)
- Mehta S** See **Connelly S** Jt Auth; **Knippel JJ** Jt Auth; **MacAulay S** Jt Auth
- Mejia AB**
Therapeutic dilemmas with anticonvulsant medications (Abs) PPC 29
- Merali T** See **Pao D** Jt Auth
- Merkley J** See **Leblanc K** Jt Auth
- Mohamed S** See **Chan J** Jt Auth
- Muise T, Hiltz N, Slayter K, Haase D**
Point prevalence of hyperlipidemia in HIV patients (Abs) PPC 49
- Muise T, Slayter K, Forward K**
Efficacy of meropenem utilizing different dosing strategies (Abs) PPC 57
- Neil Pollinger D** See **Chan J** Jt Auth
- Newby B**
Assessment of empiric vancomycin regimen in neonates (Abs) PPC 49
- Newby BD, Thongthai K**
Migrating angioedema possibly related to angiotensin-converting enzyme inhibitor (CR) 136
- Nguyen A, Louie S, Blocka J, Roelants H, McCrea P, McClure M**
An assessment of academic detailing (Abs) AGM 29
- Nickerson A, Saulnier L, Roberts N, MacKinnon N**
Outcome analysis of a pharmacist-directed seamless care service (Abs) PPC 35
- Nieuwstraten C, Dolovich L, Chase H**
Goal attainment scaling in the provision of pharmaceutical care to hospitalized patients with cardiovascular disease: A pilot study (A) 262
- Nolan R** See **Chan J** Jt Auth
- Ong S, Tailor SAN**
Application of personal digital assistants to an infectious diseases consult service (L) 281
- O'Reilly KV** See **Tsuyuki RT** Jt Auth
- Painvin C** See **Weinstein S** Jt Auth
- Pao D, Bhajan-Mathur S, Lee M, Kwan A, Barbiero K, Blatman B, Cheung T, Thambirajah S, Ting G, Yung E, Merali T, Berry S, Hsu T, Jetha S, Manzano C**
Highlighting 10 years' experience with a pharmacist-directed warfarin nomogram program at a community hospital (Abs) PPC 48
- Papastergiou J** See **Cornish P** Jt Auth; **Shamiss Y** Jt Auth
- Paradiso-Hardy F**
The bottom-line on non-ST elevation acute coronary syndromes (Abs) PPC 35
See also **Shamiss Y** Jt Auth
- Paradiso-Hardy F, Bucci C, Bartle B, Madorin P**
Pharmacy-based heparin-induced thrombocytopenia surveillance program for heart valve replacement patients (Abs) 169
- Paradiso-Hardy F, Bucci C, Madorin P, George K, Bartle B**
Pharmacy-based heparin-induced thrombocytopenia surveillance program for heart valve replacement patients (Abs) PPC 49
- Park-Wyllie L**
HIV post-exposure prophylaxis (PEP): Taking the "PEP" out of the "prick" (Abs) PPC 38
- Patel A, Czerniawski B, Lui E, Gray S**
Randomized, controlled trial assessing the efficacy of the topical amethocaine gel to reduce pain in infants undergoing heel pricks (Abs) PPC 48
- Paton T** See **Weinstein S** Jt Auth
- Pearson G, Yuksel N, Card D, Chin T, Gray M, Hawbold J, Jackevicius C, Slavik R, Thompson A**
An information paper on pharmacist prescribing within a health care facility (IP) 56
Statement on pharmacist prescribing (S) 55
- Pearson GJ** See **Yuksel N** Jt Auth
- Pearson GJ, Taher TH, Dzavik V, Reteff EM, Woloschuk BL, Francis GA**
Tolerability of statin-fibrate and statin-niacin combination therapy in dyslipidemic patients at high risk for cardiovascular events (Abs) PPC 52
- Pharand C**
How to evaluate pharmacoeconomic data: The example of enoxaparin in acute coronary syndromes (A) 114
- Pho K**
Gene therapy in oncology (Abs) PPC 44
- Pierce S** See **Horwood S** Jt Auth
- Poloway L**
La SCPH se démarque encore / CSHP—Still making a difference (POR) 181 / 184
- Popovski Z** See **Salama SE** Jt Auth
- Pradhan R, Bonnici A, Lefebvre P**
Formulary reconstruction after the amalgamation of four tertiary care hospitals to form the McGill University Health Centre (MUHC) (Abs) AGM 30



- Quinn I** See **Ensom RJ** Jt Auth
- Rao M** See **Ledger S** Jt Auth
- Reteff EM** See **Pearson GJ** Jt Auth
- Richardson J**
Rheumatoid arthritis—New guidelines & therapies (Abs)
AGM 27
- Ritchie M**
Use of an in house database to promote seamless care and ongoing patient monitoring in an outpatient oncology clinic (Abs) AGM 30
Use of an in-house database to promote seamless care and ongoing patient monitoring in an outpatient oncology clinic (Abs) PPC 59
- Roberts N** See **Nickerson A** Jt Auth
- Rocchi Dean M** See **Austin Z** Jt Auth
- Rodger M** See **Boucher M** Jt Auth
- Roelants H** See **Nguyen A** Jt Auth
- Rogers K, Tierney M, Singh A, McLean W**
Assessment of a seamless care prescription/discharge note form (Abs) PPC 57
- Rosenbloom D, Ginsberg JS**
Arguments against monitoring levels of anti-factor Xa in conjunction with low-molecular-weight heparin therapy (A) 15
- Ross I** See **Salama SE** Jt Auth
- Rowe M** See **Bayliff CD** Jt Auth
- Saibil F** See **Cornish P** Jt Auth
- Salama SE, McLeish N, Abraham P, Ross I, Banerjee A, Hewitt G, Toprani G, Popovski Z, Leob M**
Empiric antibiotic prescribing in the intensive care unit (Abs) PPC 54
- Salsman BM**
Keeping our patients safe—A pharmacist's perspective on medical error & medication safety (Abs) AGM 17
- Saulnier L** See **Nickerson A** Jt Auth
- Sawoniak AE, Shalansky KF, Zed PJ, Sunderji R**
Formulary considerations related to warfarin interchangeability (PP) 215
- Schillemore C** See **Austin Z** Jt Auth
- Schindel T**
Self-directed learning—Myths and challenges (Abs) AGM 26
- Schufeld K** See **Shamiss Y** Jt Auth
- Schuster B, Semchuk B, Sulz L**
Development and implementation process for a pharmacists educational strategy in the Regina Health District (Abs) PPC 51
- Schuwirth L** See **Vaillancourt R** Jt Auth
- Semchuk W**
Enhancement of medication utilization for patients undergoing cardiac surgery (Abs) PPC 48
See also **Schuster B** Jt Auth; **Tsuyuki RT** Jt Auth
- Seto W, Trope A, Bath J, Mathew M, Hales B, Walker SE**
Short-term stability, accuracy, and homogeneity of morphine concentrations in syringes stored at 24°C (Abs) PPC 53
- Shalansky K, Carr D, Marra F, Mallinson A**
Pharmacist utilization of the DIE test to assess aminoglycoside vestibulotoxicity (Abs) 170
- Shalansky KF** See **Sawoniak AE** Jt Auth
- Shalansky S** See **Harder C** Jt Auth
- Shamiss Y, Paradiso-Hardy F, Papastergiou J, Khaykin Y, Schufeld K, Madan M, Cohen E**
Risk stratification, therapeutic management, and clinical outcomes of patients with non-ST elevation acute coronary syndromes: A Canadian university-affiliated hospital perspective (Abs) PPC 54
- Shear N** See **Weinstein S** Jt Auth
- Shevchuk YM** See **Wlodarczyk K** Jt Auth
- Singh A** See **Rogers K** Jt Auth
- Sirdevan M** See **Wong C** Jt Auth
- Sketris I** See **Cooke C** Jt Auth
- Slavik RS**
Retrieving and appraising systematic reviews (Abs) AGM 22
See also **Pearson G** Jt Auth
- Slyater K** See **Horwood S** Jt Auth; **LeBlanc J** Jt Auth; **Muise T** Jt Auth
- Song K** See **Kwok L** Jt Auth
- Stiver HG** See **Marra F** Jt Auth
- Sulz L** See **Schuster B** Jt Auth
- Sunderji R** See **Leung VWY** Jt Auth; **Sawoniak AE** Jt Auth
- Szeto J** See **Brown G** Jt Auth
- Szeto J, Brown G**
Impact of collaborative drug therapy management by pharmacists (L) 333
- Taddei A**
Pharmacist-initiated intravenous to oral sequential therapy (Abs) AGM 25
- Taher TH** See **Pearson GJ** Jt Auth
- Tailor SAN** See **Ong S** Jt Auth
- Thambirajah S** See **Pao D** Jt Auth
- Thompson A** See **Pearson G** Jt Auth
- Thongthai K** See **Newby BD** Jt Auth
- Tierney M** See **Boucher M** Jt Auth; **Rogers K** Jt Auth
- Ting G** See **Pao D** Jt Auth
- Tisdale JE**
Be still my quivering heart: Culprits and mechanisms of drug-induced arrhythmias (Abs) PPC 33
Teaching and mentorship: Invaluable contributions to the profession / Enseignement et mentorat : de précieuses contributions à la profession (E) 192 / 195
- To E, Jackevicius C**
Quality improvement initiative for pharmacist-assisted warfarin dosing: implementation and evaluation of a new protocol (A) 105
- Toprani G** See **Salama SE** Jt Auth
- Trentowsky S** See **Chan J** Jt Auth
- Trope A** See **Seto W** Jt Auth
- Tsuyuki RT**
Pharmacists improving patient outcomes in congestive heart failure: Results of the REACT study (Abs) PPC 32



Tsuyuki RT, Fradette M, Bungard TJ, Johnson JA, Ashton T, Gordon W, Ikuta R, Kornder J, MacKay E, Manyari DE, O'Reilly KV, Semchuk W

Improving the use of ACE inhibitors in patients with congestive heart failure: The review of education on ACE inhibitors in congestive heart failure treatment (REACT) study, stage I (Abs) PPC 50

Tsuyuki RT, Fradette M, Johnson JA, Bungard TJ, Ashton T, Gordon W, Ikuta R, Kornder J, MacKay E, Manyari DE, O'Reilly KV, Semchuk W

A randomized trial of a patient support program for patients with congestive heart failure: The review of education on ACE inhibitors in congestive heart failure treatment (REACT) study, stage II (Abs) PPC 55

Turnbull K, Bielech M, Walker SE, Law S

Stability of oxycodone hydrochloride for injection in dextrose and saline solutions (A) 272

Twaites L See **Bayliff CD** Jt Auth

U D

Medication safety alerts (PP) 52, 143, 219

U D, Hyland S

Medication safety alerts (PP) 278

U D, Jelincic V

Medication safety alerts (PP) 330

Vaillancourt R, Gutschi LM, Ma J

A pharmacist-based lipid clinic: Development and implementation in the Canadian Forces (Abs) PPC 59

Vaillancourt R, Ma J, Winslade N, Schuwirth L

Evaluation of prescribing competence among physician assistants in the Canadian Forces (Abs) PPC 55

Vaillancourt R See **Guillemette M** Jt Auth; **Gutschi LM** Jt Auth

Vecchiarelli D See **Leung F** Jt Auth

Vercaigne LM See **Wlodarczyk K** Jt Auth

Virani A

Overcoming the side effects of antidepressants (Abs) PPC 29

See also **Crown N** Jt Auth

Wai AO See **Jewesson P** Jt Auth

Walker SE

Brave new world? (FC) 300

The Human Genome Project (FC) 4

Peer review and the publication process (Abs) PPC 37

Pharmacogenomics (FC) 188

Treating genetic disease (FC) 96

Who owns your genes? (FC) 248

See also **Draves AH** Jt Auth; **Seto W** Jt Auth; **Turnbull K** Jt Auth

Walker SE, Chan J, Law S

Stability of dolestron in normal saline and 5% dextrose in water solutions stored at 4°C and 24°C in syringes (Abs) PPC 50

Walker SE, Karra K, Yeung M, Law S

Stability and compatibility of hydromorphone with either bupivacaine or ropivacaine in minibags stored at 4°C and 24°C (Abs) PPC 59

Walker SE, Law S

Stability and compatibility of granisetron alone and in combination with dexamethasone in 0.9% sodium chloride and 5% dextrose in water solutions (A) 27

Waller R See **McLean W** Jt Auth

Wazny LD, Brackbill ML

Lepirudin dose recommendations for treatment of heparin-induced thrombocytopenia in patients undergoing intermittent hemodialysis (CR) 39

Webb JM, Kent DA

What's the buzz? Identifying local patterns of drug abuse (Abs) AGM 32

Weinstein S, Paton T, Shear N, Bain D, Holness L, Painvin C

The Workplace Safety and Insurance Board and Sunnybrook and Women's College Health Sciences Centre: A unique partnership (Abs) PPC 54

Wetmore SJ See **Karakashian S** Jt Auth

Wichman K

Telehealth Ontario—Pharmacists providing medication information to the public (Abs) PPC 40

See also **Austin Z** Jt Auth

Wichman K, Hertz S, Kwon JJH

Medication information by telephone: Requests reflect the needs of patients (Abs) AGM 29

Wilbur K

Anti-factor Xa monitoring in overweight and obese patients (L) 336

See also **Curran R** Jt Auth

Willis GA See **Daws D** Jt Auth

Winkelbauer S

Development and delivery of certificate programs for pharmacists (Abs) AGM 28

Winslade N See **Vaillancourt R** Jt Auth

Wlodarczyk K, Makowsky MJ, Vercaigne LM

Impact of pharmaceutical care on dialysis patients' knowledge (Abs) PPC 57

Wlodarczyk K, Zello GA, Shevchuk YM, Leson CL

Total parenteral nutrition practices in Canadian neonatal and pediatric care units: Results of a survey (A) 254

Woloschuk BL See **Pearson GJ** Jt Auth

Wong G See **Fernandes O** Jt Auth; **McTaggart B** Jt Auth

Wong C, Sirdevan M, Hogg A, Heffer M

Neonatal care: The pharmacists' perspective (Abs) PPC 42

Woodworth S, Bayliff CD, George CFP

Diltiazem-induced ileus (Abs) PPC 60

Wyllie ARJ

Getting to know botulinum toxin (Abs) PPC 39

Yamashita S

Effect of live lactobacilli yogurt preparation in enterally fed patients with antibiotic associated diarrhea (Abs) PPC 59

See also **Chant C** Jt Auth; **Leung L** Jt Auth

Yamashita S, Drynan J

Comparison of low dose (1 µg) cosyntropin and conventional dose (250 µg) cosyntropin for adrenal insufficiency testing in the critically ill (Abs) 170

Yeung M See **Walker SE** Jt Auth

Yoong D See **Connelly S** Jt Auth

Yuksel N See **Pearson G** Jt Auth

Yuksel N, Pearson GJ

Prescriptive authority for pharmacists: Where are we?

Where are we going ? (Abs) PPC 30

Yung E See **Pao D** Jt Auth

Zarnke K See **Connelly S** Jt Auth

Zed PJ See **Leung VWY** Jt Auth; **Sawoniak AE** Jt Auth

Zello GA See **Wlodarczyk K** Jt Auth

Zerjav S

Optimizing the treatment of depression: Strategies for
augmenting and combining antidepressants (Abs)
PPC 27

Zvonar R See **Fairbairn J** Jt Auth

